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Cone-beam computed tomography (CBCT) is a commonly used imaging technique in
radiation therapy. Images are acquired prior to radiation therapy treatment to assess
changes in patient anatomy and correct any errors in patient positioning. CBCT is an
x-ray modality and its use for imaging includes a dose to the patient. This study aims to
calculate the dose of ionizing radiation received during conebeam computed tomography
(CBCT) imaging. Monte Carlo (MC) methods were used to perform these dose calcula-
tions. The CBCT scanner examined in this study was the Varian Truebeam X-ray Imager
(XI). The present study is comprised of two main parts:
• Construction and validation of a MC model of a CBCT imager. The scanner was
modelled using the GATE MC simulation toolkit. The results simulated by the
model were compared with experimental measurements. Precise dose measurements
were then made to convert the simulated dose into experimental dose for a given
x-ray tube potential.
• Estimation of organ doses and effective dose in a human phantom. The GATE
CBCT model was used to perform MC dose calculations in a population-based com-
putational phantom. The absorbed dose calculations were converted into effective
dose to evaluate the risk of developing secondary cancers due to CBCT imaging. Pa-
tient organ doses were analysed by dose-volume histograms (DVHs) and expressed
using the minimum dose delivered to 50% and 10% of the organ volume, D50% and
D10%.
For the latter part of the study simulated and measured percentage depth doses (PDD)
and profiles were compared. PDDs matched within 2% while profiles matched within
10%. Experimental measurements were performed in an anthropomorphic phantom us-
ing thermoluminiscent dosimeters (TLDs). Simulated and experimental results from the
anthropomorphic phantom were compared to calculate an energy-specific MC calibration
factor. The average difference between simulated and experimental results was 13.7% for
pelvis CBCT and 6.4% for head CBCT.
Effective doses were measured for the three main CBCT scan protocols: head and neck,
thorax, and pelvis. The pelvis effective dose was the highest at 3.91 mSv ± 0.11 mSv.
Thorax CBCT imaging, which uses an identical beam energy and geometry to pelvis
imaging but lower mAs, had an effective dose of 1.72 mSv ± 0.07 mSv. Head CBCT
imaging uses a lower beam energy and varying beam arrangement to the other sites. The
effective dose for head CBCT was 0.289 mSv ± 0.020 mSv.
DVHs were evaluated for six different sites using the three main CBCT imaging protocols.
The D50% and D10% were calculated for radiosensitive OARs. For pelvis CBCT imaging,
centred on the prostate, the dose at the centre of the scan was 16.9 mGy. For selected ra-
diosensitive organs the bladder (D50%=18.7 mGy, D10%=22.4 mGy), rectum (D50%=17.8
mGy, D10%=18.7 mGy) received the highest absorbed dose. For thorax CBCT imaging,
centred in the mid-lung region, the centre dose was 5.1 mGy. For selected radiosensitive
organs the heart (D50%=3.58 mGy, D10%=4.85 mGy) and lungs (right: D50%=3.89 mGy,
D10%=5.27 ; left:D50%=2.22 mGy, D10%=3.59 mGy) received the highest absorbed dose.
For head CBCT imaging, centred on the brain, the highest doses were received when the
partial gantry rotation was through the anterior structures of the head. DVH analysis
of the eyes showed D50% was around 6 mGy while the D50% of the brain and spinal cord
were 2.45 mGy and 1.87 mGy.
The intention of this study was to provide dose detriment and treatment planning data
for CBCT imaging using the XI scanner. The DVH data is intended to provide estimates
to be used during radiation therapy treatment planning.
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1 Introduction
X-rays are used extensively in clinical procedures for the diagnosis and treatment of dis-
ease. The use of x-rays in the treatment of cancer is the predominant application of
radiation therapy. Radiation therapy uses treatment modalities that produce high doses
of focal radiation to disrupt tumourous tissue, increasing the probability of cell death or
halting its proliferation. By stopping the progression of tumour cells the likelihood of
spread into surrounding healthy tissue is reduced.
Over the years, radiation therapy has developed greatly. A pivotal addition to the field
was the introduction of linear accelerators (linacs), a high energy x-ray modality that
treats tumours with a beam that originates outside of the patient. linacs are one of the
most common methods for radiotherapy treatment as the high energy x-rays can be used
to treat deep seated tumours that are often surgically inoperable. To treat a tumour while
avoiding damage to healthy tissue structures the x-ray beam is conformed to the shape of
the tumour. The need for accuracy in radiation therapy necessitates the use of individ-
ualised patient treatment plans. These plans are based on computed tomography (CT)
image studies acquired before the beginning of treatment. Through the use of advanced
treatment planning software, the dose deposition in individual patient anatomy can be
accurately simulated. Recently technologies that improve the utility of radiation therapy
include. Techniques such as intensity modulated radiotherapy (IMRT) and stereotac-
tic radiotherapy (SRT) are employed by linacs to improve their ability to deliver highly
conformal therapies. These radiation therapy delivery methods, in combination with 3D
volumetric patient imaging and treatment planning software, have vastly improved the




The use high doses of conformal radiation leads to the potential of a geometric miss for
a tumour volume. These delivered doses have steep dose dropoffs outside of the targeted
tumour and missing the target will result in significant underdoses to tumour volumes
while overdosing healthy tissue. Image guided radiotherapy (IGRT) is technique applied
to verify patient setup prior to radiation treatment. Images are acquired directly prior
to treatment delivery while a patient is lying on the treatment couch. By delineating
the tumour volume and surrounding anatomical landmarks clearly the patient’s position
relative to the intended dose distribution of the delivery can be clearly visualised. Set-up
corrections may be made in an attempt to eliminate these misalignments and provide
geometric verification of a tumour volume.
In order to delineate bone and soft tissue in IGRT cone-beam CT (CBCT) can be used.
CBCT is an imaging technique used in diagnostic scanners that are integrated into a linear
accelerator. CBCT acquires a 3D volumetric image set of a patient over a large imaging
area, eliminating the need to move a patient through a scanner to attain an image. The
3D volumetric images are compared to the patient’s original CT image and any changes
in the patient anatomy can be evaluated as the treatment proceeds.
The use of CBCT imaging does involve a concomitant dose to the radiotherapy patient.
The imaging doses from CBCT devices are largely excluded from the treatment planning
dose calculation due to their relative magnitude to the therapeutic dose. The doses are
typically around two orders of magnitude smaller than the delivered treatment dose.
However, CBCT imaging involves a wide field of view and the dose distribution is not
targeted to the tumour volume. This means that a homogeneous dose is delivered across
the field, to both tumour and healthy tissue.
CBCT images may be acquired every day of a patient’s treatment or once every week.
For some of the most frequently imaged tumours, such as prostate cancer, CBCT imaging
has been found to cause doses exceeding 5% of the therapeutic dose.5 Based on current
2
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radiobiological models for radiation-induced cancer risk doses of these magnitudes may
not be negligible in the development of secondary cancers. Many believe that these doses
should therefore be quantified and incorporated into radiotherapy treatment planning.
The ability to simulate the dose from low energy x-rays in treatment planning systems
has been studied in the past with some success.6,7 Although due to limiting assumptions
for the modelled energy spectra and x-ray interactions the accuracy of these methods is
questionable for routine patient dosimetry. For the most accurate assessment of treatment
planning doses Monte Carlo methods can be used. Monte Carlo can be used to simulate
the elementary particles of x-rays and track their transport through space, calculating
the energy deposited from elemental interactions with matter. Monte Carlo methods are
considered the gold standard of radiation therapy dose calculation and are widely used.
1.1 Thesis objectives
This thesis is split into two main objectives:
• To develop and validate a Monte Carlo model for CBCT dose calculation
• To perform Monte Carlo dose calculations for site-specific CBCT imaging protocols
To achieve the former of these two objectives the GATE Monte Carlo toolkit will be used.
The CBCT scanner examined is the Varian x-ray imager (XI) which is Varian Truebeam
integrated device. The model will be validated using experimental measurements. Once
validated the doses calculated by simulation will be converted into absorbed dose by
deriving a Monte Carlo calibration factor.
For the latter objective, the calibrated dose calculations will be used to simulate dose
in an anthropomorphic phantom. Analysis of these dose calculations will enable the
determination of organ doses and the estimation of radiation-induced cancer risk from






When treating a tumour volume with ionizing radiation the objective is the death of all
tumour cells. The death of all the cells can be considered synonymous with the death
of the tumour as a whole. It is known, however, that during a delivery of radiation
not all cells will be killed. The survival probability of cells in an irradiated volume
decreases exponentially with increasing radiation dose.8,9 Mathematical radiobiological
models are used to describe the relation between physical quantities of radiation and
biological response. The survival fraction probability for large cell populations can be
calculated using a Poisson probability distribution and the linear-quadratic (LQ) model
of radiobiological response.8,10
SF = exp−αD−βD2 (2.1)
where SF is the surviving fraction of the cells, D is the dose delivered to the tumour and
α and β are empirical constants characteristic to the cell. The relationship in equation 2.1
is used to plot cell survival curves such as that shown in figure 2.1. The curve plots the
Figure 2.1: Linear-quadratic cell survival curve
surviving portion of a cell population on a logarithmic scale against dose on a linear scale.
From equation 2.1 and figure 2.1 it is seen that the shape of the curve depends on only
4
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the linear (α) and quadratic (β) parameters. In fact, the ratio (α/β) of the parameters
turns out to be pivotal in estimating the radiation response of a given cell population.
For example a low α/β value is observed for normal tissues that have a delayed death
response to increasing doses of ionizing radiation. By contrast, high α/β values are seen
in early responding and tumourous tissues.11
Figure 2.2: The linear-quadratic model is used for modelling cell survival curves. demon-
strating a) The linear and quadratic components are marked b) Cell survival curves for
early responding (curve A) and late responding (curve B) tissues.
By observing the cell survival curves in figure 2.2 it can be seen that late responding nor-
mal tissues (low α/β ratio) are preferentially spared over early responding tissues (high
α/β ratio) at low doses. α/β ratios vary for different tissue types and choosing the best
pattern of dose deliveries for radiation treatment will depend on their values. The benefits
of low dose fractionation on normal tissue survival is seen in the theoretical model shown
in figure 2.3. The figure displays the early response of tumourous tissue at low doses.
As radiation dose increases, both tumour control and normal tissue toxicity increase. To
improve the probability of controlling the tumour while minimising the normal tissue
complications the early sensitivity of tumours can be exploited. The desired outcome
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from radiation therapy is to maximise the dose effect relationship for tumour control and
minimise the relationship for normal tissue toxicity.8 The difference between the two
curves is referred to as the therapeutic index, which is a distribution which measures the
therapeutic effect of radiation against the toxicity caused. To achieve the desired out-
comes of radiation therapy the therapeutic index should be maximised.
Figure 2.3: A theoretical model showing the sigmoidal dose response of both tumorous
tissue and healthy tissue to ionizing radiation. As shown the damage response of tumorous
cells is activated at a lower dose threshold than that of normal cells. The difference
between the two dose response curves is known as the therapeutic index (TI). The TI
compares the therapeutic effect from a given dose to the amount of toxicity it causes.
2.2 Radiation therapy
Radiation therapy is the treatment of cancer with ionizing radiation. External beam
radiation therapy is a method of radiation therapy delivery in which radiation is delivered
to a tumour from a source external to the patient. EBRT is commonly delivered with a
linear accelerator (linac - figure 2.4). A linac is a high energy x-ray modality that can
be used to treat deep seated tumours that would otherwise be unable to receive surgical
intervention. The x-ray beam produced by a linear accelerator is shaped to conform closely
6
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Figure 2.4: A Varian Clinac linear accelerator
to the shape of a tumour. In this way a therapeutic dose may be delivered to the tumour
volume while sparing the healthy surrounding tissue. A linac is capable of delivering a
conformal x-ray beam from a number of static or moving positions to a tumour volume.
The linac rotates around a central position in 3D space known as the isocentre. This
point is a fixed distance of 100 cm away from the x-ray beam source at all angles. The
isocentre is used to mark the centre position of a treatment. For the purposes of this
study radiation therapy can be divided into three main steps: Imaging and delineation,
planning, and verification and treatment
2.2.1 Imaging and delineation
Delineation of a tumour volume is vital in radiation therapy. By accurately identifying
a tumour volume a therapeutic dose can be planned to cover the entire extent of the
disease. CT imaging is vital during this step. A CT scan is the first step in planning
radiotherapy. An image is acquired of the patient over an area containing the tumour
volume. The image visualises the internal anatomy and the position of the patient on
the treatment couch. Reproducible positioning of the patient relative to the treatment
couch is important as it needs to be replicated when the patient is later treated with
a linac. Immobilisation devices are used to hold the patient’s position throughout the
procedure. An external laser system that is aligned with the centre of the imaging plane
7
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of the CT is also used for patient setup. Before a scan marks are drawn on the patient’s
skin to aid in relating the patient position to the imaging plane. The marks on the patient
are later tattooed to the patient’s skin and are used for setup relative to the linac isocentre.
The CT image is a volumetric image set of the tumour and its surrounding anatomy. As
part of the treatment planning process the following volumes are defined on the image
set:
• The gross tumour volume (GTV) is the volume that consists of the visible extent
of the tumour and any metastatic disease. This volume is often defined by prior
clinical examination. For tumours that do not have well defined boundaries other
imaging techniques, such as MRI and PET, can be superimposed on to the CT
image to identify the extent of disease.
• The clinical target volume (CTV) is an expansion margin around the GTV. In some
cases lymph nodes or other tissues surrounding tissues may be at risk and require
treatment. The CTV is based on the site and biological behaviour of a specific
tumour type.
• The planning target volume (PTV) is a margin expansion of the CTV. It is a
geometric concept and accounts for an uncertainties in patient setup, anatomical
positioning or linac dose deliverability. Dose in radiation therapy is prescribed to
this volume.
• Organs at risk (OAR) are normal tissue volumes that are in close proximity with
the tumour volume. OARs are radiosensitive structures that are at risk of being
damaged by radiation. These structures are given specific dose constraints that
should not be exceeded during treatment planning.
The volume that is actually treated during radiation therapy will, in general, be larger
than the PTV (figure 2.5). This depends on the treatment technique used. Additional
regions of interest (ROI) may also be defined for individualised treatment plans.
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Figure 2.5: Radiotherapy treatment planning volumes. Volume definition is required for
3D treatment planning software to measure accurate dose-volumes. Adapated from Pave1
2.2.2 Planning
Once the tumour and OARs are delineated on the image set a treatment plan is developed.
At this step decisions are made about x-ray beam geometries and beam arrangements
used to treat the PTV. The need for accuracy in radiation therapy dose delivery requires
detailed dose calculation capabilities. These calculations are performed on the patient-
specific CT image set to maximise the possible therapeutic index of the treatment and
improve patient outcomes. A treatment planning system (TPS) is a software system used
to develop complex plans based on these image datasets to calculate 3D dose distributions.
Treatment plans will use a beam arrangement that may consist of one to several fields with
varying beam energies, angles, movements and intensities. An optimal beam arrangement
will ensure that the prescribed dose is delivered to the treatment volumes whilst minimiz-
ing the dose to OARs. After the beam arrangement is established, the dose distribution
to the patient volume can be calculated. The accuracy of the dose calculation in a TPS is
dictated by the accuracy of the underlying dose calculation algorithm. Deficiencies exist
in these algorithms and may be effected by patient external contour, x-ray beam shaping
and modification, and tissue heterogeneities. It is important to know which scenarios dif-
ferent algorithms can be used in. After the dose distribution is calculated it is displayed




A 3D dose distribution contains a lot of data and the dose received by the delineated
volumes needs to be displayed in a meaningful way. Dose-volume histograms (DVHs) are
generally used for dose evaluation of a treatment plan. Cummulative DVHs (shown in
figure 2.6) plot the percentage volume of a structure on the vertical axis against dose on
the x-axis. To explain how DVHs are interpreted the critical structure (or OAR) in figure
2.6 is examined. The dose on the x-axis represents the minimum dose that is received by
the highest dose exposed portion of that volume. For exampled the minimum dose re-
ceived over the highest exposed 50% of the critical structure is 22 Gy. The minimum dose
received by the structure will increase as the volume becomes smaller. In this case the
volume will be receiving at least 44 Gy in the most exposed 10%. The dose progression
continues until the smallest examinable volume is measured. At this volume the structure
which will be receiving the maximum dose.
For radiotherapy dose reporting DVHs can be annotated in the form of simple dose met-
rics. In the case of figure 2.6, the minimum dose received over the highest exposed 50% of
the critical structure is denoted D50%=22 Gy. The minimum dose received by the highest
exposed 10% of the critical structure is D10%=44 Gy. DVHs are used to evaluate how
uniformly a prescribed dose is delivered to a PTV and to check the dose received by an
OAR is within its dose constraints.
2.2.3 Verification and treatment
When a treatment plan is approved and ready to treat it is transferred to a linear accel-
erator. Prior to radiation treatment the patient is immobilised on the treatment couch
in the same manner as during CT imaging. The tattoos placed on the patient during
CT imaging are used for alignment with the in-room laser system. The lasers intersect
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Figure 2.6: A cumulative dose-volume histogram (DVH). The first bin of the histogram
contains the volume of the structure that will receive at least 0 Gy (100%). The remaining
bins are used to analyse the minimum dose that is received for a given volume of the
structure. Adapted from Podgorvsak (2006)12
through the isocentre of the linac in the saggital, coronal, and transverse planes of a pa-
tient.
Verification of the tumour position is required prior to treatment delivery. A linac is
equipped with imaging systems for both kilovoltage (kV) and megavoltage (MV) imaging
which are both capable of providing delineation of anatomical structures. These images
are taken to align a patient to the centre of the treatment field, using their planning CT
image as a reference. Imaging a patient to detect and correct setup errors is a practice
known as image-guided radiation therapy (IGRT).13 Images acquired during IGRT pro-
vide visulasation of tumour and normal tissue structures. These structures are used to
match the IGRT image to the reference CT image. The best possible fit is indicated by
minimising the shift in specific matching structures, which may be soft tissue or bony
structures. The image registration parameters given from matching are used to apply
corrections to the patients setup.
Accurate and reproducible dose delivery is essential in radiotherapy. The sigmoidal dose-
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Figure 2.7: Multileaf collimator (MLC). MLCs delivered intensity modulated radiation
doses to a tumour volume over time by moving between different control points. Adapted
from Jeraj (2004)2
response curves shown in figure 2.3 demonstrate that small discrepancies in delivered dose
can have large effects on tumour control and normal tissue damage. If a tumour is mis-
aligned to a treatment field prior to radiation therapy this may result in large underdoses
for the tumour or overdoses for surrounidng health ytissue. Therefore, geometric verifi-
cation is of high importance to radiation therapy.
Once the tumour volume has been verified the radiation treatment plan is delivered. Ra-
diation is delivered using the planned beam arrangements. The delivery time will vary
depending on the technique used. Intensity modulated radiation therapy (IMRT) uses a
static beam with motion controlled tungsten leaves (multileaf collimators (MLC) - shown
in figure 2.7) to deliver x-rays with time-varied intensity over the tumour volume. The
time to deliver the treatment can be up to 6 minutes for nine static beams.14 Arc thera-
pies involve modulated beam delivery while the linac gantry rotates around the patient.




2.3.1 Computed tomography (CT)
CT (or computed tomography) is a commonly used medical imaging device for creating
3D images of the human body. CT scanners are used to acquire images for the purpose
of treatment planning in radiation therapy. The geometry of conventional CT scanners is
known as fan-beam CT. A fan-beam CT system involves the use of an x-ray tube (source),
an opposing ring shaped detector. The source and detector are mounted in a CT bore on
a slip ring that allows them to continuously rotate around a patient (Figure 2.8a).
X-rays originate from a focal point in an x-ray tube and spread in a fan beam pattern.
A fraction of the these x-rays will pass through a patient and reach the detector. The
remaining x-rays will be absorbed and scattered by interactions within the patient. These
interactions will be explained in section 3.3.
The detection of modulated x-ray beam profiles is the principle that allows for CT image
formation. The differences in x-ray attenuation through a patient produce variations in
contrast in the resulting image. Beam acquisitions at each tube angle are stored as a
projection image. Projection images are acquired over a large number of angles around
the patient (Figure 2.8b). The images are then reconstructed and compiled to provide an
estimate of the inner structures.
The reconstructed image matrix is a 3D representation of the human anatomy which is
comprised of voxels (Figure 2.9). Each voxel has a value that represents an attenuation
value for the x-rays that have passed through the human anatomy. The increase in atten-
uation coefficients are visually represented as a linear progression in grayscale intensity.
The Hounsfield unit (HU) scale is a linear transform of these attenuation coefficients in
which the radiodensity of water at standard temperature and pressure is defined as zero.




Figure 2.8: CT scan a) a basic diagram with labelled CT components b) Projection images
are acquired from a large number of angles to construct a 3D representation of the patient
inner structures. Figure from Kalender, W. A. (2011)15
Figure 2.9: A CT image is comprised of transverse slices. Each transverse slice is a




defined using the following equation
HU = 100× µ− µwater
µwater − µair
(2.2)
where µ represents the linear attenuation coefficient of the material, µwater is the linear
attenuation coefficient of water, and µair is the linear attenuation coefficient of air.
The collimation of the fan beam and width of the detector elements determines the imag-
ing resolution of anatomy in the superior-inferior direction (Figure 2.8b). The width of
the fan beam is typically on the order of 1 cm.5 To image larger volumes the patient couch
is translated through the bore of a CT scanner while images are acquired by the rotating
source and detector. If the patient couch is translated in discrete steps and imaged at
each stopping point it is known as an axial scan (Figure 2.10a). If the patient couch is
translated continuously while imaging it is referred to as a helical scan (Figure 2.10b).
To image a large volume, without translating the patient couch, both the fan beam and
the detector can be widened in the direction of the couch travel (axial direction). This
geometry is known as Cone beam CT.
(a) Axial scan (b) Helical scan
Figure 2.10: CT scanning acquisition types
2.3.2 Cone beam CT (CBCT)
Cone-beam CT (CBCT) is a wide fan beam acquisition technique. It can be used for
diagnosis, IGRT, and treatment review. CBCT is the most common IGRT modality used
in radiation therapy.5 Unlike fanbeam CT, a cone-beam image is taken in a single gantry
15
2 Theory
rotation around a patient. The treatment couch is stationary during imaging. Because of
this the superior-inferior scanning volume is limited by the extent of the beam collimation.
An illustration comparing a fanbeam CT geometry with a CBCT geometry is shown in
Figure 2.11. CBCT is offered by most linac-integrated x-ray imaging devices (see Figure
2.12). Unlike the multi ring detectors used for fanbeam CT, CBCT images are acquired
with a high resolution 2D amorphous silicon panel detector. The x-ray unit and detector
are mounted on opposing sides of the linac.
The treatment couch remains stationary during CBCT acquistion but it is highly sus-
ceptible to motion artefacts. A full rotation takes around a minute and during this time
any patient movement can effect the quality of the image. Due to the large imaging
field scatter received by the detector panel is also significant. This leads to lower image
contrast and signal-to-noise ratio (SNR) than in conventional CT. IGRT methods such
as CBCT are used for quantifying setup error prior to treatment delivery. The utility
CBCT has over other IGRT x-ray methods is the ability to monitor changes in patient
anatomy. Changes in patient external contours or internal anatomy occur frequently over
the course of radiotherapy. These changes will affect the treatment distances and, subse-
quently, the organ dose distributions of therapeutic radiation. Large changes in patient
anatomy between the patient’s planning CT and the CBCT for the present fraction will
greatly influence the accuracy of treatment delivery. In some cases the planning CT image
is no longer valid for treatment delivery. CBCT alone provides the ability to assess these
changes prior to radiation delivery.
There are two vendors that supply CBCT systems for radiation therapy: Elekta and
Varian. Elekta produce the X-ray Volumetric Imager (XVI) while Varian produce the
On-Board Imager (OBI) and, more recently, the X-Ray Imager (XI).
2.3.2.1 Varian XI
The Varian X-Ray Imager (XI) is a CBCT scanner. It is integrated with the Varian True-
beam linear accelerator (shown in figure 2.12). It consists of an opposing x-ray source
16
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Figure 2.11: A comparison between two CT acquistion techniques. a) Conventional (fan
beam) CT. Fan beam CT uses a narrowbeam configuration to capture an image using sub-
centimeter slice widths. An object will be translated through the fan beam arrangement
until the line detector has acquired data over the volume of interest. b) Conebeam CT
(CBCT). CBCT uses a wide beam arrangement to capture an image. CBCT can acquire
an image over a much large volume for a stationary object. It is acquired at the expense
of image quality.
and detector. The source arm consists of an x-ray tube and a series of collimation ma-
terials and filters. These components can be configured to adjust the beam geometry
and energy spectrum from the x-ray tube used for imaging. There are two main beam
configurations used for CBCT imaging in the XI system. These configurations will be
referred to as the head scan protocol and the body scan protocol. The head scan protocol
uses a 100 kVp beam and full bowtie filter. It has a smaller FOV for head and neck
imaging (Figure 2.13a). The scan arc used for the head scan protocol is 200deg. The
body scanning protocol uses a 125 kVp beam and the half bowtie filter. This mode is
intended for imaging larger objects. The beam collimation is offset so that only part of the
anatomy is imaged in a single projection (Figure 2.13b). As the gantry completes a 360◦
rotation around the object a full picture of the anatomy is formed. When configured in
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Figure 2.12: A Varian Truebeam linear accelerator. The imaging components (source and
detector) are mounted on either side of the therapy beam source (treatment head)
this way, the beam arrangement reduces the skin dose recieved by the patient compared to
a full FOV. Scattered radiation is also reduced, which leads to an increase image quality.17
The bowtie filters are x-ray beam shaping tools that are mounted in front of the x-ray
source. They are made of an aluminium alloy which is thin at the centre of the beam and
increases in thickness towards the edge of the beam. The increasing thickness provides
increased x-ray attenuation towards the edge of the beam. The filter is shaped in this way
to increase the homogeneity of the dose over the patient volume.18 As there is less tissue
to pass through at the periphery of the patient less x-rays are required to pass through.
Additional benefits of the bowtie filter is an overall improvement in CT number accuracy,
image unifomrity, and contrast detectability.18
18
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(a) Head scan beam arrangment (b) Body scan beam arrangement
Figure 2.13: The XI scanner includes a source and opposing detector. The following
illustrations depict the geometry used in both a) full bowtie filter setup (employed in
head CBCT acquisition) and b) half bowtie filter setup (employed in both pelvis and
thorax CBCT acquisition). Both bowtie filters are used to selectively attenuate x-rays at
the edge of the field. Figure adapted from Wen et al. (2007)16
There is an additional filter in the head of the XI scanner for CBCT imaging. A titanium
beam hardening filter is placed immediately before the bowtie filter and preferentially
absorbs x-rays at the lower end of the beam’s energy spectrum. Low energy x-rays are
attenuated to decrease the number of x-rays attenuated in the patient, which decreases
the imaging dose recieved by the patient.
2.4 Radiation quantities
The elementary particle of x-rays and other electromagnetic waves is the photon. Photons
undergo nuclear reactions with atoms in which they transfer their energy to orbital elec-
trons. By transferring a sufficient amount energy they can overcome the binding energy
between the electron and its atomic nucleus, freeing the electron. The electron will un-
dergo inelastic collisions with neighbouring nuclei and orbital electrons, depositing energy
into its surrounding medium.
Radiation dose refers to the energy imparted to a medium per unit mass from ionizing
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radiation. Using The International System of Units (SI) absorbed dose from ionising ra-
diation is defined in joules per kilogram (J/kg). In radiation dosimetry this relationship is
denoted with the unit Gray (Gy). Another quantity used in radiation dosimetry is Kerma.
Kerma (or ”kinetic energy released per unitmass”) is the initial energy deposited in a
mass due to interactions from ionizing radiation.19 Energy transferred from x-rays to elec-
trons is deposited in a medium by collisional and radiative interactions (bremstrahlung).
This results in two components of kerma: collisional kerma and radiative kerma. This
quantity is important in the dosimetry of low energy photons, such as those used in di-
agnostic procedures, as the range of liberated electrons is short. Electrons with kinetic
energies below a few hundred kilovolts will deposit their energy within a sub-millimeter
distance of the photon interaction site. The radiative component of kerma is negligible.
So in this scenario the energy deposition is assumed to be local to the primary interaction
site and the value of kerma is numerically equivalent to absorbed dose.
Radiation dosimetry is the practice of measuring radiation quantities. In radiation therapy
dosimetric measurements from a radiation source are performed under a wide range of
beam configurations. Theses configurations use different measurement points, detectors,
and mediums. In a clinical environment it is necessary to perform dose measurements so
that a relationship between the radiation source and a human body can be established.
Absorbed dose measurements typically fall into two categories: absolute and relative.
2.4.1 Absolute dosimetry
Aside from using a calorimeter, dose can not be measured directly. However, a number
of detectors can be used to relate a measurement of ionising radiation to absorbed dose
in Gy. Absolute dose measurements are standardised measurements that can be used as
baseline data and reported across radiotherapy departments. Absolute dose is measured
under controlled reference conditions, termed reference dosimetry.20 Reference dosime-
try is an accurate dose measurement performed under conditions stipulated in published
guidelines. The measurements are performed under conditions that are practical to relate
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the radiation source to the position of a tumour. The reference conditions are given from
published guidelines and stipulate measurement geometries, choice of detector and correc-
tion factors to apply to measurements. The set conditions are used to accurately measure
a point dose in Gy. Measurements are often made in objects known as phantoms that
are specially designed measurement objects that mimic human anatomy. The phantoms
are often water-based as the radiation scattering and absorption properties of water are
similar to human tissue.
A calibration factor is used to convert the chamber’s response to dose in Gy. The calibra-
tion factor may be given in terms of either absorbed dose or kerma. The factor is trace-
able to a primary standard as part of the international measurement system. Accredited
Dosimetry Calibration Laboratories (ADCL) develop and maintain primary standards
for radiation measurements. These standards are compared with other standards labs
worldwide to keep consistency in measured quantities.
2.4.2 Relative dosimetry
Often tumours will be treated under conditions that vary from the conditions used in
reference dosimetry. Relative dosimetry measurements are performed to relate reference
dosimetry measurements to a range of clinical conditions. The relationship established
between the source and a human body from absolute dosimetry can therefore be adjusted
for several different exposure scenarios.
One common scenario involves a change in depth of a tumour. If a tumour depth varies
from that measured in reference dosimetry the output can be adjusted using a percentage
depth dose (PDD) factor. As an x-ray beam traverses a medium it loses energy from
attenuation and scattering. A PDD relates the absorbed dose deposited by a radiation
beam with depth in a medium. The dose values are normalised by dividing their values
by the maximum dose, referred to as dmax. A PDD for a 6 Megavolt beam is seen in figure
2.14a. As shown the maximum dose of a 6 MV x-ray beam will be deposited at around
21
2 Theory
1.5 cm deep in a body of water under a 10 cm x 10 cm field. For kilovoltage x-rays the
maximum dose is deposited within a few millimeters from the water surface.21 This poses
problems in reliably determining the dmax of kV beams.
Reference dosimetry is performed at a given depth through the centre of a radiation beam.
For a completely uniform beam it would be expected that doses measured at a distance
off the central axis of the beam would be identical to the centre. However in practice
this is not seen. The off axis ratio is quantified to determine the dose at a point off the
beam centre relative to the central axis. By plotting the off-axis ratio along length of the
radiation field the dosimetric profile of the beam is given (figure 2.14b. Off-axis ratios
can be determined for differing field sizes and depths.
(a) Percentage depth doses (b) Dosimetric profiles
Figure 2.14: Relative dosimetry data for a 6 Megavolt x-ray beam in water. Different
square field sizes for the beam are indicated by the legend
2.5 Radiation detectors
Radiation dosimetry is one of the key areas of application for detectors. Detectors can be
used to measure both absolute and relative dose. Some detectors can be used to measure
the dose delivered to a patient during radiation therapy treatment.19
An ideal radiation detector will produce accurate and precise readings over a range of
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setup and source conditions, have a linear response to dose over a range of exposures,
have a low detection threshold for low dose exposures, be tissue equivalent, and have high
spatial resolution.
This section will explore the principles of operation of the radiation detectors used in this
work. Additional theory for dose calculation with these detectors will also be included.
2.5.1 Ionisation chambers
Ionization chambers are one of the most widely used radiation detectors.19 An ionisation
chamber is essentially an anode and a cathode separated by a gas-filled chamber. There
is a potential difference applied between the anode and cathode to create an electric field.
When a charged particle enters the electric field it interacts with the molecules of the
gas. If the particle deposits energy to an atom that exceeds its ionization energy thresh-
old an ion pair will be created. Ion pair creation relates to how much energy has been
deposited in the gaseous medium. Positive ions from the ion pair will move towards the
cathode while free electrons flow towards the anode. The electrons are registered at the
anode as an electronic pulse. These pulses are usually too small to measure directly. The
electrons from multiple ion pair creations are allowed to accumulate before a current is
measured. The current measured over a discrete time interval is equivalent to the charge
measured by the chamber which is related to dose by the use of a ADCL calibration factor.
Ionisation chambers are the primary detector used to perform reference dosimetry in a
clinical. Ionisation chambers (Farmer-type) have a small energy dependence over a range
of diagnostic and therapeutic energy levels.21 However, an ionisation chamber’s response
is sensitive to a number of conditions. Air density, exposure rate, ion recombination losses
and electric field polarity will all effect the ion pair collection rate.22 These factors are
accounted for by reference dosimetry protocols.
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AAPM TG61 reference dosimetry protocol
The American Association of Physicists in Medicine (AAPM) established a protocol for
the reference dosimetry measurement of kilovoltage (kV) energy x-rays. The measurable
range for this protocol is 100 kV to 300 kV. The absorbed dose to water is determined at










Where Mpl is the chamber reading corrected for ion recombination, polarity, temper-
ature, presuure, and electrometer response (nC), Nk is the air-kerma calibration factor
adjusted for the spectrum of the user’s beam (mGy/nC), PQ,chamber is the chamber correc-
tion factor which accounts for the individual response a chamber, and [(µen/ρ)wair]water is
the water-to-air ratio of the mean mass energy-absorption coefficients, measured in water.
Each variable in equation 2.3 is derived from the half value layer (HVL). HVL is an
important precursor value for TG-61 reference dosimetry. All the variables involved in
dose calculation are provided in tabulated lookup tables which are indexed by their HVL
value. The HVL is a quantity related to the ’quality’ of an x-ray beam. It is defined as
the thickness of a specified material that is required to attenuate the air kerma rate of a
narrow beam to half its unattenuated value. It is expressed in mm of thickness of high
purity aluminium or copper.
2.5.2 Thermoluminescent dosimeters
Thermoluminiscent dosimeters are crystalline materials used for radiation dosimetry. The
principle of operation relies on the radiation luminiscnece of the crystalline structure.
When undergoing a photon interaction energy is transferred to electrons in the valance
band of crystalline atoms. The energy given to the electron elevates it to a higher energy
”conduction” band. Due to defects in the crystalline atomic structure the electrons do not
recombine with the vacancy in the shell. The electron-hole pair are captured in ”traps”
between the valance and conduction band. An electron trap represents a metastable
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state of the atom (Figure 2.15a). By adding thermal energy to the system trapped
electrons can exceed the activation energy required to move back into the valance band
(figure 2.15b. In the valance band electrons will recombine with the electron holes. The
recombination process results in the emission of a photon of energy equal to the gap
between the conduction and valance band. For a TLD this band gap energy (on the order
of 1 eV) results in the emission of visible light.
To exceed the activation energy for each electron trap heat is delivered to the system.
(a) (b)
Figure 2.15: Electron energy level transitions in a TLD material (a) An incident photon
interacts with an orbital electron and gives it sufficient energy to move into the conduction
band. It is then trapped in a metastable state due to defects in the crystalline structure
(b) when sufficient thermal energy is applied the trapped electron returns to the valance
band emitting heat and visible light
There may be multiple band gaps in a TLD structure and sufficient thermal energy must be
supplied for visible light emission from different trap ”depths”. A TLD reader will supply
an increasing amount of heat until emissions are measured from all possible metastable
states. A photo multiplier tube is used to amplify the signal from the emissions. The
reader will display the intensity of these emissions as a function of temperature. A typical
glow curve produced by a TLD reader is seen in figure 2.16
TLD-100
The most commonly used TLD material is Lithium Floride doped with with magnesium
and titanium (TLD-100). Lithium floride has similar radiation interaction properties
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Figure 2.16: A glow curve given by a Harshaw TLD reader. The intensity in nA is a
measure of thermoluminscence at a given temperature. There is a fixed rate of heating
up until the main thermolumiscence peak. After this the temperature stays fixed and
measures any residual emissions.
to human tissue for kilovoltage x-rays.22–25 This means the material will absorb and
scatter photons to the same extent as irradiated tissue. TLD-100s have suitable detection
thresholds for low x-ray dose applications. Del Sol Fernández et al. found the minimum
detection threshold for TLD-100 dosimeters was below 1 mGy.25 The group also found
that the dose response of TLD-100 dosimeters was linear over a range of diagnostic x-ray
doses. However, TLDs have been shown to have large energy responses for kilovoltage
x-ray beams.21 It is therefore recommended that in the range of 20 - 250 kVp beams they
be calibrated using the same beam energy they are intended to be applied with.
TLD dose calculation
The light output of a TLD when readout in a TLD reader is measured in charge (C).
To relate the reading to an absorbed dose value there are a number of factors that must
be accounted for. Absorbed dose is caclulated for an indivdual TLD by the following
formula:
Di = MiSCFiNw,batch (2.4)
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where the dose, Di, is given in mGy, M is the charge measured during TLD readout
(nC), SCF is the sensitivity correction factor of the TLD, and Nw,batch is the TLD batch
calibration factor (mGy/nC).
The SCF is a unique value that is assigned to each TLD. It accounts for the individual
variation among a group of TLDs under the same exposure conditions. Applying individ-
ual SCFs can reduce the relative standard deviation from a batch of TLDs from around
20% to a few percent.25 These variations arise due to the difference in crystalline structure
of each TLD. For a batch of TLDs irradiated to equal dose the SCF for a TLD in that







Where Rij denotes the jth readout for the iit chip in a batch. To attain an acceptable
relative standard deviation for a chip SCF it should be irradiated multiple times. For a







Nw,batch is an energy-dependent calibration factor. It converts the light output of a TLD
to a value in kerma or dose. To measure the calibration factor TLDs must be irradiated
under reference conditions with a calibrated instrument that holds a calibration factor
traceable to an Accredited Dosimetry Calibration Laboratory (ADCL).
2.6 CBCT dosimetry
The dose from CBCT imaging in radiation therapy is often overlooked due to its small
magnitude relative to therapeutic doses of radiation. In most cases the dose is not quan-
tified as part of a radiation therapy treatment plan. However studies of CBCT dose have
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shown that these doses may not be insignificant over an entire course of radiation therapy
treatment. Some studies have shown that the dose from CBCT can exceed 5% of the
therapeutic dose.5,26,27 Islam et al. measured doses from the Elekta XVI in a cylindrical
phantom and reported doses of up to 35 mGy per scan.28 Studies of the Varian OBI have
reported organ doses of up to 100 mGy (for OBI v1.3) and 60 mGy (OBI v1.4) per scan.29
Studies comparing the two scanners side-by-side have confirmed these values.30,31
Many studies have sought to quantify the dose delivered from CBCT imaging. Com-
mon methods include the use of indirect measurements such as dose indicies in stan-
dardised cylindrical phantoms.32–34 Other methods involve direct measurement, using
TLDs or other dosimeters to measure absorbed dose in-vivo or in an anthropomorphic
phantom.16,30,35,36 To relate absorbed dose to radiation-induced cancer risk radiation
protection properties such as effective dose can be used. Monte Carlo simulations have
also been used by a number of groups.5,37–42
2.6.1 Low dose radiation exposures and secondary cancer risk
With the exception of fluoroscopy perceptible acute effects of radiation (deterministic
effects), such as skin reddening and hair loss, are not seen in diagnostic x-ray irradia-
tions. The risk that is posed by imaging radiation dose is the stochastic risk of cancer
development. These are long term effects that are not well understood due to a lack of
epidemiological evidence.43,44 However, a number of studies do suggest that low doses of
radiation pose a statistically significant increase in cancer risk.43–46
Studies of survivors of the atomic bombings in Hiroshima and Nagasaki provide the best
data on risk estimates for development of secondary cancers. The studies involve a very
large sample size of subjects of varying ages, genders, and received doses. This includes
subjects that were present during the bombings but far enough away from the bomb site
to have received a negligible to no radiation exposure from it. Long-term follow-up stud-
ies on cancer development in these populations discludes the influence of demographic
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and lifestyle factors that may be confounding factors.44 There are limitations in the data
due to inaccuracies in dose estimation and tracking of survivors. However, these studies
represent the best avialbe data to represent the relationship between dose and cancer
risk. The data has been used to form the basis for the dose-risk models that are currently
applied in radiation protection practices.
Despite the lack of epidemiological studies there is further difficulty in assessing the long-
term risks posed by CBCT imaging due to the concomitant therapeutic dose. The inability
to separate these doses results in further limitations for the dose risk posed by CBCT.
There are many studies on the risk of secondary cancer development following radiation
therapy. After surviving from a primary malignancy, 17%-19% of patients will go on to
develop a secondary malignancy.47–49 These factors will vary due to factors such as the
age, genetic predispositions, the anatomical site studied, and the dose and volume of the
irradiated site.50 The most site-specific data comes from Cervical and prostate cancer
follow up studies. These studies show a significant link between these patients and the
development of secondary cancers in the pelvic region, where the highest dose is deliv-
ered.51 Increases in cancers of the lymphatic system, bone and kidneys were also observed.
A controlled study for malignant prostate tumours found 6% increase in secondary cancer
onset when treated with radiation therapy compared to surgical intervention.52
In light of the lack of follow up data and confounding factors from radiation therapy imag-
ing, risk is generally assessed through the use of radiation induced cancer risk estimation
models. These models are based on data from radiation workers and the atomic bomb
survival data.43 This data is controversial for low doses due to the imprecisions mentioned
above. This leads to many conflicting findings at low doses. As radiation risks are more
readily determined at high doses low radiation dose risks can be determined by means
of extrapolating this data. The commonly used linear no-threshold relationship implies
proportionality between dose and cancer risk. The approach is based on the premise that
damage to DNA from in-vivo studies appears linear between 1 mGy and 100 Gy.50,53 The
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linear no-threshold model is used in radiation protection and assumes that any dose of
ionizing radiation can initiate the carcinogenesis. In order to estimate risk based on this
model the effective dose descriptor can be used. This quantity will be covered later in
this chapter.
2.6.2 Indirect dose measurement
Indirect measurements are output measurements that can be performed to benchmark
the radiation output of the CT procedure. They do not represent the dose received by a
patient. Indirect measurements generally rely on the use of single parameterised index.
CTDI
The most commonly used index is the computed tomography dose index (CTDI).5,33 The
CTDI is a radiation exposure parameter for conventional CT scanners. It quantifies the
average absorbed dose for a single axial slice of a CT scan.5,32,33,54 The CTDI is quantified






Where N is the number of transverse slices acquired during a scan
T is the thickness of each transverse slice
D is the radiation dose profile along the z-axis
From observing the integral boundaries in equation 2.7 it is clear that measuring the
average dose profile over an infinite range is not practical to measure. The CTDI is






The CTDI100 is measured in an acrylic, cylindrical phantom. The CTDI phantom comes
in two sizes: head (16 cm diameter) and body (32 cm diameter). Both phantoms are 15
cm long. Size standardisation is used in these phantoms for reference dosimetry. CTDI100
measurements are performed in the centre of a CTDI phantom. But there are a number




CTDIw is a weighted CTDI index. It is calculated using five measurement points in a
CTDI phantom, one in the centre and 4 at the periphery. The measurement points are






Equation 2.9 can be applied to a series of adjoining helical or axial scans.
2.6.2.2 CTDI limitations
The CTDI measurements are made up from both primary and scattered radiation in the
CTDI phantom. For conventional CT the primary beam will be measured but scattered
radiation is underestimated. The scattered radiation field extends throughout the length
of the CTDI phantom and into the surrounding air. The 100 mm length ionisation cham-
ber will therefore underestimate the scattered radiation component. An IAEA report
found that using the CTDI100 collects only 82% and 63% of the scan dose for the head
and body phantoms, respectively.55 Mori et al. found that, for a 2 cm beam width, the
CTDI phantom length needed to be doubled to measure 90% of the dose. When compared
to the use of a 450 mm ionisation chamber the CTDI100 was found to underestimate dose
by as much as 50%, irrespective of beam width.
Extension of the CTDI concept to large field scanning systems such as CBCT provides
further limitations for the concept. The CTDI is applied to quantify the integrated dose
over a couch translation in the z-axis. A CBCT scan is taken in one rotation around the
patient and no couch translation is applied. The beam widths employed in z-axis also
exceed the size of the CTDI phantom. This leads to large underestimations in the scatter
dose profile when measured with the 100 mm ionisation chamber.38,56 Studies have shown
that as beam width increases, the weighted dose index CTDIw decreases. Over a large




A number of methods have been applied to extend the CTDI concept to cone-beam
CT scanners. For example, Amer et. al derived the cone-beam dose index (CBDI)
which uses the same pencil ionisation chamber and CTDI phantom but evaluates the
dose to the central 100 mm portion rather than the entire beam width. Many alternative
configurations have been proposed for CBCT dosimetry. The point that is made in this
work, however, is that these indicies are indirect measures and do not provide information
on absorbed dose received by a patient.
2.6.3 Direct dose measurement
Direct dose measurements have a number of implementations in radiology and radiation
therapy. As they are related to patient doses the measurements should be performed
in-vivo. Direct measurements can be performed using a large range of radiation de-
tectors. These includes TLDs, optically stimulatd luminiscent dosimeters (OSLD), or
diodes. Given the practical and ethical limitations of performing in-vivo dosimetry, di-
rect measurement studies can be performed in anthropomorphic phantom volumes or by
computational simulations.
2.6.3.1 Effective dose
Measuring absorbed dose alone is not sufficient to assess long term development of can-
cer. The mechanisms of radiation-induced cancer and genetic damage rely on the type of
radiation depositing the dose and the type of tissue being irradiated.
The ICRP protection quantities, equivalent and effective dose, are dose descriptors that
sum the absorbed dose to organs to provide a single number for comparing with dose
limits and constraints for low dose x-ray procedures. The dose descriptors are intended
to provide a correlation between whole-body radiation exposure and stochastic effects.
There are three steps involved in the calculation of effective dose. Firstly, the absorbed
dose to organs and tissues is determined in Gy. As different radiation types differ in
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their ability to cause biological damage the next step involves calculating equivalent dose.
Equivalent dose weights different radiation types in their ability to cause cancer per unit





Where DR is the absorbed dose from an exposure to a type of radiation, R multiplied by
its biological weighting factor, WR. The result is expressed in Sieverts (Sv). For x-ray
exposures the biological weighting applied to the dose is 1. So for a CBCT exposure
the equivalent dose and absorbed dose are numerically equivalent. The final step of
calculation invovles the summation of equivalent doses to differnet tissues, multiplying











Where WT represents a weighting factor for a specific tissue of a human organ and HT rep-
resents the equivalent dose received by that organ. The tissue weighting factor represents
the cpntribution of each tissue to total detriment from a whole-body irradiation. Effec-
tive dose is also determined in the quantity Sieverts (Sv). The concept of effective dose
is intended for reference models and not to individual subjects. The atomic composition
of anatomy used in anthropomorphic phantoms can be standardised. For a standardised
phantom the ICRP tissue weighting factors can be used (figure ??).
Effective dose has been calculated for the XI scanner in two differnet studies. A study
by Pyone et al.57 determined effective doses for the XI CBCT scanner using cone beam
dose index measurements. The imPact CTdosimetry software was used in this study. The
software was originally designed for fanbeam CT and characterises CT scanners by the
ratio of peripheral to central CTDIw and central to in-air CTDIw measured in a CTDI
phantom. From these quantities it uses a empirical factors from Monte Carlo calculated
data to derive organ doses for an ICRP humanoid phantom. Pyone et al. extended the
imPACT software to CBCT by calculating CTDIw from CBDI measurements. Their
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study examined the three main scan protocols for head, thorax and pelvis imaging. The
effective doses for head, thorax and pelvis imaging were 0.1 mSv, 2.4 mSv, and 4.9 mSv,
respectively (table 2.1). The study makes no mention of the scan parameters used to
conduct this analysis.
A small study by Hauri et al. examined the effective dose from different XI pelvis imaging
protocols using experimental measurements.58 They found that the effective dose for
standard pelvis CBCT imaging was 5.4 mSv (table 2.2). The study was carried out using
TLD measurements at 183 measurement locations in the whole body RANDO phantom.
Only the dose to the gonads could not be measured and was instead estimated.
2.6.3.2 Monte Carlo methods
As stated previously organ doses can be difficult to measure in-vivo or by other experi-
mental methods. The use of detectors with resolution and spatial limitations makes some
absorbed dose information hard to collected. Monte carlo methods are used to simulate
photon transport through space, calculating absorbed dose based on the fundamental in-
teractions of photons with matter. MC simulations possess all the qualities of an ideal
radiation detector list in section 2.5. Doses can be measured with effectively unlimited
resolution and the dismissal of spatial limitations. The dose deposition can be scored
across a region of interest at any location within a simulated environemnt. Computa-
tional phantoms can be constructed on CT image datasets to provide retrospective dose
analysis. Monte Carlo simulations can be performed accurately if the the transport pa-
rameters in the model are akin to reality. Detectors are used to verify the accuracy of the
simulation parameters for both relative and absolute dosimetry.
An extensive explanation of Monte Carlo methods and how they are applied in this work
is given in chapter 3.
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Table 2.1: Organ and effective doses for XI scan protocols. The doses were evaluated by
Pyone et al using the ImPACT CT dosimetry software
Head Thorax Pelvis
Organ dose (mGy)
Gonads 0.01 0.00 19.00
Bladder 0.00 0.00 34.00
Esophagus 0.00 10.00 0.00
Liver 0.00 0.44 0.13
Thyroid 0.42 0.76 0.00
Bone surface 0.95 3.10 6.10
Brain 2.50 0.04 0.00
Salivary glands 2.50 0.04 0.04
Skin 0.23 1.00 4.40
Bone-marrow (red) 0.22 1.60 4.00
Colon 0.00 0.02 9.30
Lung 0.02 5.70 0.01
Stomach 0.00 5.70 0.20
Breast 0.00 6.60 0.02
Remainder 0.25 1.40 3.10
Total effective dose (mSv) 0.1 2.4 4.9
35
2 Theory



















Total effective dose (mSv) 5.4 ±0.27
*adrenals, extrathoracic region, gall bladder, heart, kidneys, lymphatic nodes, muscle,
oral mucosa, pancreas, prostate, small intenstine, spleen, thymus
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Table 2.3: ICRP recommendations for effective dose tissue weightings59
Tissue wt
Gonads 0.08
Red bone marrow, Colon, Lung, Stomach, Breasts, remaining tissues* 0.12
Bladder, Liver, Esophagus, Thyroid 0.04
Skin, Bone surface, Salivary glands, Brain 0.01
*adrenals, extrathoracic region, gall bladder, heart, kidneys, lymphatic nodes, muscle,
oral mucosa, pancreas, prostate, small intenstine, spleen, thymus
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tem
Monte Carlo (MC) simulation is the gold standard for performing radiation transport
calculations.3,60 MC methods provide capabilities for solving radiotherapy problems that
can not be attained by experimental or analytical methods.60,61
A MC approach was taken to study the dosimetry of the Truebeam XI scanner. The XI
contains multiple components to shape and modify intensity of the x-ray beam of the
scanner. Each of these components had to be correctly modelled in order to provide a
valid beam model of the system. The x-ray spectrum is the first component that must
be validated. The remaining components are then included in constructing a beam model.
This chapter contains a brief introduction to MC simulations before detailing the work
performed to model the XI system. This introduction covers fundamental concepts, differ-
ent packages and techniques for radiation therapy transport problems and the estimation
of uncertainty from MC simulations.
3.1 Introduction to Monte Carlo
The MC method is a statistical operation involving the repeated random sampling of a
system to obtain numerical results. MC methods are applied to modelling physical and
mathematical systems where the probability of different outcomes are not easily predicted
due to the intervention of random variables. This makes the MC method suitable in
application to radiation transport problems.
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3.1.1 Random number generation
The idea of randomness in MC simulation is not entirely in line with the mathematical
definition. Sampling in MC calculation is performed using a sequence of randomly gen-
erated numbers. MC algorithms use a procedure known as random number generation
(RNG). RNG produces uniformly distributed random numbers over a defined interval
(usually [0 1]). This process is not truly random as a procedure used by a computer is in-
herently deterministic.62 The correct terminology used to describe the process is pseudo
random number generation. Pseudo-RNG is a more practical method than using true
random number generation for sampling sequences. This is due to reusability and storage
considerations for these sequences.60,62 A sequence must appear sufficiently random. As
such there must be no evidence of correlation between the numbers. This means that the
sequence of numbers must be sufficiently large so as not to be resused. The number of
primary photons simulated can be on the order of billions. RNG algorithms must have a
sufficiently large generation cycle to far exceed the number of generated primaries.61
3.1.2 Probability distribution
Random number sequences are used in MC sampling to draw random variables from prob-
ability distribution functions (PDFs). PDFs are weighted functions which represents an
underlying physical process in a MC system. They provide a list of possible outcomes of
a random variable from a given process. In radiation transport problems these variables
may be photon direction or momentum as they traverse a medium. Essentially in MC
simulation a sequence of random numbers are mapped to a PDF and are used to obtain
the random variables needed to represent particle transport phenomena.
Cross sections
The interaction experienced by a photon in a medium depends on the cross section of
the medium. The cross section is a description of the probability of a collision between
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two particles interacting under certain conditions. Simulated photon cross sections are
based on theoretical calculations and evaluated data.63 In MC simulation cross sectional
data is selected based on the photon energy examined. The data used will determine the
probability distribution for photon interactions in a given medium.
3.1.3 Photon transport simulation
After being drawn from PDFs the sampled random variables are used in MC numerical
integration. Essentially the results obtained from MC calculations are the outcome of this
numerical integration. The MC method is suited to the evaluation of integrals which an
analytical solution can not be attained for. MC methods are applied to integrals which
model physical and mathematical systems with many coupled degrees of freedom.64 These
integrals have multiple dimensions to solve across and complicated boundary conditions.
Radiation transport problems requires numerical integration to solve coupled Boltzmann
transport equations (BTE). The degrees of freedom in the coupled BTEs are theoretically
unlimited due to infinite number of possible secondary photons and electrons that can
be produced. MC methods use a time-independent linear Boltzman transport equation
(LBTE) to solve radiation transport problems.61,64–66 The LBTE is a set of partial dif-
ferential equations that determine the spatial and energy distributions of photons and
electrons. The LBTE for photon transport is represented by the following
Ω̂ · ~∇Φγ + σγt Φγ = qγγ + qeγ + qγ (3.1)
Where Φγ is the photon (γ) fluence, σγt is the total photon cross section, and Ω̂ is a
unit direction vector. The right hand side of equation 3.1 contains the source scatter
terms. qγ is the primary photon source term, qγγ represents scattered photon-to-photon
interactions, and qeγ represents scattered photon-to-electron interactions.
Electron (e) transport is given by the following LBTE
Ω̂ · ~∇Φe + σetΦe −
∂
∂E
(SRΦe) = qee + qeγ + qe (3.2)
Where SR is the restricted collisional and radiative stopping power of electrons.
40
3.2 GEANT4 Application for Tomographic Emissions
The LBTE approximation does not model the self interaction of photons and only con-
siders scatter in a medium. Under this approximation photons can be independently
simulated one after another. This lowers the computational requirements by decreasing
the amount of memory required to perform simulations.64
Photons are continuously sampled as they traverse a medium. As the photon interacts
both equations 3.1 and 3.2 are used to solve the local electron fluence, Φe. Dose is then





Where φe is the local electron fluence, SR is the material specific stopping power, and E
is photon energy.
Dose is scored in MC simulations as mean value per incident particle from the primary
source. Dose distributions are aggregated as a simulation proceeds and a dose grid is
output for analysis.
3.2 GEANT4 Application for Tomographic Emissions
GEANT4 Application for Tomographic Emissions (GATE) is one of the many MC codes
available for radiation transport simulation. GATE is an application based off the GEANT4
simulation toolkit. The GEANT4 MC code was originally developed by CERN for high-
energy photon physics applications. It is an extensively verified code system for radiation
transport.67 It is a object orientated programming language implemented in C++. For
radiation specialists with no background in object orientated programming the time taken
to learn this skill set can be prohibitive to using GEANT4. High-level scripting languages
that overly GEANT4 can be used as an alternative. One such language is GATE.
GATE was first released in 2003.67 It was originally intended to be used for positron
emission tomography and single photon emission tomography applications. In the years
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since its initial release simulation capabilities for CT and radiotherapy have been added.68
Since then it has been used in a number of studies for imaging and dosimetry applications
in medical physics.40,68,69
A number of MC codes purposed specifically for radiation therapy applications are avail-
able. These include BEAMnrc, TOPAS, and XVMC.70 GATE possesses a number of
features that may favour its use over alternative code systems. GATE inherits a number
of these features from GEANT4 that make it useful for not only radiation therapy, but
also dosimetry and imaging problems. The code has a high degree of flexibility for the
input of simulation geometries. This provides a user with more configurations options
when fine tuning a beam model. Dose ’actors’ are used to simplify the handling of dose
scoring. GATE includes a voxelised source input which is easy to parameterize and elim-
inates the need to use a phase space file.67,70,71 An inbuilt virtual clock allows the simple
simulation of time-dependent phenomena (e.g. gantry rotation).
A recognised disadvantage when using GATE for radiation therapy is the simulation effi-
ciency compared to other established codes.70 This is due to a lack of variance reduction
techniques (VRTs). VRTs help speed up simulation times without the loss of calculation
accuracy. The most recent version of GATE (version 8) includes a number of VRTs that
greatly improve simulation efficiency for modelling low energy electromagnetic processes.
These techniques will be examined in section 3.4
GATE simulations are run from a primary job file or ’macro’. Smaller macros may be
linked to the primary. Each macro contains an ordered list of scripted commands to
establish a component of the simulation. For radiotherapy and dosimetry the commands
describe the following components: Geometry of the beam model and phantom, dose
scoring grids used, physics processes applied, source description and execution options.
When a simulation is run a series of messages are relayed to the user to tell them the
status of the aforementioned aspects of the simulation. The messages allow a user to
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troubleshoot a failing simulation. At the end of a simulation the result from scoring grids
and other output variables are stored in individual files for analysis.
3.3 Photon interaction processes
A photon may interact several times before depositing all of its energy. Interacting through
a variety of photon interaction processes, the photon transfers its energy to charged par-
ticles in the medium. The interactions can be simulated using the total cross section
data mentioned in section 3.1.2. The interaction length of a process is the mean distance







where σ is the cross section of the process for an atomic component n of a medium. The
interactions considered in this work are the photoelectric effect, Compton scattering, and
Rayleigh scattering. The cross section for Thomson scattering is too small for low energy
processes to be considered here.
3.3.1 Photoelectric effect
During the Photoelectric effect a photon is completely absorbed and transfers all of its
energy to an orbital electron. If the energy exceeds the binding energy of the electron it
is ejected from its shell. The energy of the outgoing electron is
E = hv − L (3.5)
Where hv is the energy of the photon and L is the binding energy of the electron. The
vacancy will lead to a cascade of electron transitions from the outer shells to the inner
shells. These transitions will produce a cascade of emissions such as characteristic X-
rays, Auger electrons, or Coster-Kronig electrons. The photoelectric effect cross section
depends on the photon energy and atomic number, Z, of an atom. The photoelectric cross
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As the atomic number, Z, of a material increases and photon energy, E, decreases the
likelihood of the photoelectric effect increases rapidly.
3.3.2 Rayleigh scattering
Rayleigh scattering, or coherent scattering, occurs when the binding energy of an electron
is similar to the incoming photon energy. During the interaction all the electrons of an
atom contribute so that momentum is conserved. The photon is deflected and no energy
is transfered to the target. Scatter is mainly forward-directed and coontributes less than
10% to the relative interaction cross sections in tissue and water (Figure 3.1)
3.3.3 Compton scattering
Compton scattering, or incohorrent scatter, will occur when the incoming photon energy
is greater than or equal to the binding energy of the electron. The interaction results in
the electron being ejected from its atomic shell and the photon being scattered. TThe
energy of the scattered photon is the difference between its initial energy and the binding
energy and kinetic energy of the ejected electron. The Compton cross section is dependent
on the electron density and photon energy. The Klein-Nishina treatment of the Compton
differential cross section is based on the assumption that the electron is free and stationary.
However this assumption is invalid for low energy processes where binding effects and more
significant.72
3.4 Variance reduction techniques
Variance quantifies how far a set of numbers are spread out from their average value. The
error variance given in a MC simulation is σ2/N . An insufficient number of generated
photons, N will lead to the output data being restricted by noise. The obvious way to
reduce statistical fluctuations in the data is to increase the number of photons generated.
During MC simulation photons are tracked one at a time which saves memory useage but
can lead to long computation times. To avoid excessive computation times for an increased
value of N there are techniques to reduce the variance, σ2 of data output. Variance
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Figure 3.1: Relative interaction cross sections (i.e. attenuation coefficient) for the Pho-
toelectric effect, Compton scattering, and Rayleigh scattering as a function of photon
energy. Reproduced from NASEM (2015)73
reduction refers to a set of techniques that aid analogous (standard) MC simulations
by reducing statistical fluctuations without changing the number of events simulated.
Variance reduction techniques (VRT) are used in MC simulation to optimize transport
parameters without losing a significant amount of calculation accuracy. In other words,
correctly parameterising a VRT will result in a reduction in error variance without varying
the validity of the physical processes being modelled. Some common VRTs are photon
splitting, range rejection, and kerma approximation.74
3.4.1 Photon splitting
During MC simulation a lot of CPU time is wasted tracking photons that have little
or no effect on the simulation output. Photon splitting can be applied to place more
importance on photons that effect simulation output. In regions of the simulation with
photon splitting applied an interacting photon is split into nsplit subphotons, each carrying
a weight of 1/nsplit. Subphotons are traced to the next interaction point. The interaction
type is sampled and the electron distribution is generated. The output is weighted by
nsplit.
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3.4.2 Range rejection
Without VRTs MC simulations will track particles until they leave the system boundary
or deposit all their energy in secondary interactions. Range rejection is a technique that
can be applied to any particle tracking. If a photon is transported with a range that
does not exceed a cutoff parameter it will not be transported further and its remaining
energy will be deposited locally. The value for the cutoff parameter selected for photon
transport is chosen from one of two circumstances: 1) The range of the photon is small
compared to the size of the voxel it is traversing or 2) The photon energy below the cutoff
value will have a negligible contribution to the scored dose. Range rejection is one of the
most effective VRTs for improving MC efficiency.74,75 However, setting the range rejection
cutoff too high will increase the statistical fluctuations of a simulation. The default range
rejection threshold for GATE is 1 mm.
3.4.3 Kerma approximation
Low energy photons produce electrons with very short path lengths in tissue-equivalent
mediums. Transport of secondary electrons may not be necessary to simulate for these
small path lengths. Kerma approximation switches off electron transport and photons
are transported by ray tracing methods through voxels. Kerma approximation techniques
are one of the most effective VRTs used to improve MC efficiency for low energy x-ray
simulations.74,75 Kerma approximation VRTs are appropriate to use in a simulation pro-
vided the range of electrons released from a photon interaction is much less than the voxel
resolution in the scoring plane.
Kerma approximation is implemented in GATE using the track length estimator (TLE)
and split-exponential track length estimator (seTLE).69,76 These are both included as dose
scoring options available in GATE, making the TLE and seTLE options a hybrid of both
dose scoring and VRT.
TLE assumes a continuous energy deposition from photon tracks. Ray tracing is a light
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tracing technique that is used to simulate the average dose distribution expected from
a large number of identical photons through the voxelised volume. Photon fluence is




Where L is the distance travelled through the voxel between collisions and V is the volume







is the mass-energy absorption coefficient and E is the energy of the photon. The
seTLE dose actor combines splitting with the TLE technique. The splitting strategy is
carried out as mentioned in the above section. When using seTLE, however, both primary
and secondary photons are split into nsplit subphotons. seTLE provides similar levels of
accuracy to the TLE while increasing the efficiency by a factor of between 13 and 15.76
3.5 Expression of MC uncertainty
For experimental measurements it is possible to calculate uncertainty based on the meth-
ods given in the guide to the expression of uncertainty in measurement (GUM).77 The
methods express an uncertainty Uc(y) in terms of a measurand y. An equation that





where u(xi) represents the standard uncertainties of all input quantities. In practices such
as radiation oncology where health and safety are a concern expanded uncertainties can
be given for a measurement.
Up = kpuc (3.10)
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where kp represents the coverage factor corresponding to a confidence level p. NIST
primary standards for all dosimetric quantities in medical physics use k=2, corresponding
to an interval with a 95% level of confidence.
The standard uncertainty of an input quantity u(xi) must be represented by a type A
or type B evaluation method. Type A uncertainty is evaluated by statistical methods.
GATE simulations include a statistical uncertainty value that is scored for each voxel
in a scoring grid. These uncertainties are reduced by increasing the number of primary
photons generated or employing variance reduction.
Type B uncertainties are evaluated using methods other than statistical ones. There are
several sources of type B uncertainty in MC simulations. These include influence from
simulation geometry, radiation source, transport parameters used and the specific inter-
action cross sections used. Their influence is not evaluated in MC simulations.
MC calculations are performed using statistical modelling. A mathematical relationship
between the MC result and randomised input variables cannot be easily attained. Eval-
uating type B uncertainties would require an extensive sensitivity analysis. This analysis
is outside of the scope of this work and all MC uncertainties are reported as type A.
3.6 Methods
The GATE MC toolkit (version 8.1 - released 23/4/2018) was used to simulate the head
of the Truebeam XI system. GATE v 8.1 was built from the GEANT4 (v 10.03) envi-
ronment. Simulations were run on a workstation with a single 8 core Intel Xeon E5620
processor with a processor clock speed of 2.4 GHz.
The specification of components of the XI were given from manufacturer documentation.
A schematic diagram of the XI head unit can be seen in Figure 3.2. The components that
have an impact on patient dose are considered. They include the x-ray tube, collimators
and any added filtration.
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Voxelised phantoms were modelled using image data and require appropriate image nav-
igation algorithms to determine how the image data is handled in the simulated envi-
ronment. The ImageNestedParameterisedVolume algorithm was used in this work. The
navigation algorithm supports both analyze and MetaImage image file formats.
GATE includes a large variety of physics models which are inherited from GEANT4. For
this work the emlivermore package was used. The package uses cross sectional data from
atomic shell cross section data rather than empirical cross section data due to the high
dependence of the low energy processes on atomic shell structure.63,78
Atomic relaxation was also enabled. Atomic relaxation is a component of the emliver-
more model which simulates the physics processes of x-ray fluorescence and Auger electron
emission.79
The RNG algorithm used was the Mersene Twister (MT). the MT algorithm uses a cycle
period of 219937−1 when generating number sequences.80 This number greatly exceeds the
maximum number of primary photons that can be simulated in GATE, 2.2 billion. The
MT algorithm pregenerates random number sequences for sampling rather than generating
them on-the-fly. This leads to a reported 3 to 4 times reduction in total computation
time.61
3.6.1 Benchmarking the GATE installation
It is difficult to create a reproducible benchmark test for MC simulations due to statistical
fluctuations from random sampling. As stated in the previous chapter absorbed dose is
scored as mean value per incident photon in MC simulations. For experimental measure-
ments the number of photons generated are generally unable to be counted. Without
the ability to count photons experimentally other methods are needed to validate a MC
application.81
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Figure 3.2: The internal components of the Varian Truebeam XI head unit. The major
components are labelled A) x-ray tube B) x-ray tube window C) direction of beam travel
D) upper (Y-axis) collimators E) lower (X-axis) collimators F) beam hardening filter G)
Bowtie filter (representation only) H) detection cover
To assess the low energy dose scoring capabilities of GATE and verify correct installation
a simple benchmark test was used. The test provides a theoretical dose scoring calculation
benchmark for MC applications.
D =
(




Where E is the x-ray potential (V), Eelectron is the elementary charge of an electron
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Figure 3.3: An OpenGL visualisation of the simulated x-ray tube.
(1.60×10−19. J), N is the number of primaries and m is mass of the scored medium (kg).
The density of water used to calculate the mass was 1000 kg/m3. This is the value used
in the materials list in GATE.
For the GATE simulation a 20 keV monoenergetic beam was placed at the centre of water
medium. The dose was scored over a volume 30 cm x 30 cm x 30 cm. The resolution
of the scoring plane was set to 1. 1000 primary events were generated and a single dose
value was scored.
Both simulated and calculated dose values equated to 1.187x10−13 Gy for the above
parameters. The simulation was performed using the standard dose actor and the TLE
option in GATE. The difference in values was 2×10−4%.
3.6.2 Modelling the XI spectrum
The GS-1542 is a multi-energy diagnostic x-ray tube. It is used for radiographic imaging,
fluroscopy, and CBCT. In this study the x-ray spectra used for CBCT acquisitions were
simulated in GATE using manufacturer documentation. The spectr
The simulated environment included a voxelised source attached to a cathode, a Tungsten-
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Rhenium anode, aluminium filtration, primary collimator, and an electromagnetic actor
(Figure 3.3). A monoenergetic electron source was attached to the cathode. Both en-
ergies of 100 keV or 125 keV were used for the monoenegetic source. The position and
angle of the voxelised source resulted in beam directed perpendicular to the face of the
anode, which was offset at an angle of 14◦ from the direction of x-ray beam travel. The
focal spot size on the anode face was 1 mm diameter to match the nominal focal spot size
used for CBCT acquisition. VRTs were applied according to the recommendations given in
Mainegra-Hing and Kawrakow.82 Photon splitting was applied to multiply Bremstrahlung
interactions in the anode. Bremstrahlung interactions were split into 1,000 subphotons.
Photon and electron production thresholds in the anode material were set to 0.5 µm and
1.0 µm, respectively. Actors that stop photon and electron tracking were placed around
the cathode and anode to prevent unnecessary tracking.
The total filtration of the GS-1542 x-ray tube is given as a range in terms of aluminium
thickness. This considers both the inherent filtration due to the Beryllium window, tube
housing and cooling oil and the physical aluminium filtration present in the tube. The
aluminium thickness selected was 2.7 mm.
Figure 3.4: X-ray spectra simulated in GATE. The Monte Carlo output is given in total
counts per bin divided by the total number of primary photons simulated.
An EM scoring grid was placed 100 cm from the focal spot. This was done to effectively
eliminate the scoring of scattered radiation. The number of primaries was set to 2× 109
for the electron source. The output spectrum was stored as a histogram and the bin width
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was set to 1 kV. 2 billion primary photons were simulated to produce the spectra. The
simulated spectra for 100 keV and 125 keV sources are shown in Figure 3.4. The x-ray
spectra were comparable to those modelled in previous studies.37 The validation of the
x-ray spectra will be covered in the next chapter.
3.6.3 Beam model
All simulations in this study were run using a single, configurable macro. The following
components were included in the beam model: source, blades (collimators), beam hard-
ening filtration, bowtie filter, and detection cover. Manufacturer specifications included
dimensions, distance from source, and material composition for all components.
The source was specified first in the macro as the position of the remaining components
(a) (b)
Figure 3.5: Simulated representations of the bowtie filters used in the kV imager unit.
The figure shows (a) the full bowtie filter and (b) the half bowtie filter. The central axis of
the radiation beam passes through the red trapezoid. The gray sheet behind the bowtie
filter is the titanium filter (otherwise known as the beam hardening filter). The x-ray
beam moves from right to left.
are defined relative to its position. The voxelised source option was used to model the
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source. The x-ray spectra in figure 3.4 were used to parametrise the voxelised source
model. The source size was 1.5 mm by 1.8 mm
Beam collimation is achieved by two sets of adjustable lead blades. The first set defines
Figure 3.6: A visualisation in OpenGL of the simulated components of the TrueBeam
x-ray imager. The axis used for modelling is included in the top right of the figure.
the field size across the anode-cathode direction. The second set defines the field size
perpendicular to the anode-cathode direction. Each blade can open to a maximum of
20 cm. As such the largest field size achievable is 40 cm by 40 cm. Blade openings are
defined at 100 cm SAD.
Further filtration of the x-ray spectrum takes place downstream from the blades. The
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beam hardening filter provides preferential absorption of low energy photons. It is a high
purity titanium sheet. Below this is the bowtie filter. The filters are made from an alu-
minium alloy. The filters are shaped in the direction perpendicular to the anode-cathode
direction. Both the half and full bowtie filters, as simulated in GATE, can be seen in
figure 3.5. Both filters were modelled as a series of 1 mm long trapezoids.
Below the bowtie filter is the detection cover. The polycarbonate structure makes up part
of the plastic housing that protects the mechanical and electrical components of the XI.
The entire beam model can be seen in figure 3.6
3.6.4 Gantry rotation
The Varian Truebeam has a 360 degree range of rotation. When the gantry head is up the
indicated gantry angle is 0 degrees. Unlike fanbeam CT the rotating gantry of a linear
accelerator does not include slip ring technology. Due to this it can only rotate 180◦
clockwise or counter clockwise from 0◦ (Figure 3.7). A full 360 degree rotation will start
with the gantry head at 180◦ and end on 180E◦ (extended), or vice versa. The gantry can
rotate up to 2-3◦ past the stop point for acceleration/deceleration.
Before modelling gantry rotation in GATE it was verfifed that the relationship between
gantry angle and time was linear for a CBCT acquisition. A linear relationship is expected
as the x-ray beam does not turn on until the gantry has accelerated to a constant veloc-
ity. To check the linearity the Sun Nuclear ArcCheck phantom was used. The ArcCheck
phantom is a diode array for performing 4D measurements under radiation beams. The
phantom includes an inclinometer that records the incidence angle of a radiation beam
at each point of an acquisition.
Once the linearity between gantry angle and time was confirmed a model for gantry rota-
tion was easy to implement in GATE. The rotation was modelled for the phantom/target
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geometry instead of the beam model. The phantom/target was placed at the centre of
the simulated environment and a macro was written to apply 0.5 degrees of rotation per
time slice. For a 360 degree rotation 720 time slices were used. For a 200 degree rotation
400 time slices were used.
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Figure 3.7: The rotation coordinates for a Varian linear accelerator. If 180◦ is reached
through a counterclockwise rotation it is indexed as 180◦E (extended).
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measurements
In the previous chapter the a beam model for the XI scanner was constructed in GATE.
The Monte Carlo (MC) model can be used to calculate absorbed dose for CBCT imaging.
However, in order to validate the GATE model it had to be compared to experimental
measurements. This includes comparisons in both simple and complex geometries. These
comparisons are made to quantify any discrepancies in the GATE model for CBCT dose
calculation. The discrepancies can be used to define limitations on the use of the model
and quantify uncertainties on any findings made by simulations.
In this chapter uses experimental measurements to validate and calibrate the GATE MC
calculations into absorbed dose. This involved comparing relative dosimetry in a water
medium. Following this simulated results are calibrated against TLD measurements in
both head and pelvis anthropomorphic phantoms.
4.1 Relative dosimetry comparison
Percentage depth dose (PDD) measurements were performed in a 1D scanning (1DS)
water tank (figure 4.2a). Two 0.13 cm3 CC13 (IBA Group, Louvain-La-Neuve, Belgium)
scanning thimble ionisation chamber were used. These chambers have an uncertainty of
<2% over the range of energies investigated.83 One was placed in a motion-controlled
chamber holder and the other was fixed at a point in air to be used as an output refer-
ence (figure 4.2b). The thimble chambers were connected to a fluke electrometer (Fluke
Biomedical, Cleveland OH, USA).
A simulation was run with both simulated spectra (figure ??) in a 10 cm x 10 cm field
incident on a body of water 100 cm from the source. To verify the simulated spectra these
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Table 4.1: Factory scanning parameters used for the anthropomorphic phantom measure-
ments. ”CCW” denotes a counter clockwise scan arc from . In this study CCW scans
were performed between gantry 90◦ and gantry angle. Half and full bowtie filters are
designated by ”HBTF” and ”FBTF”, respectively. The titanium beam hardening filter is
denoted ”BHF”.
Head scan Body scan
Tube voltage (kVp) 100 125
Tube current (mA) 15 15
Pulse duration (ms) 20 20
Exposure (mAs) 147 1074
Scan arc (deg) 200 CCW 360
Filtration FBTF, BHF HBTF, BHF
Blade openings:
X1 (cm) 10.7 24.7
X2 (cm) 10.7 3.4
Y1 (cm) 14.0 14.0
Y2 (cm) 14.0 14.0
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results were compared to experimental measurements. A 10 cm x 10 cm, 100 cm SSD
depth dose measurement was made in the 1DS tank for both energies. The field size on
the water surface was verified using the light projection field from the treatment head of
the linac. The light field projected from the treatment head collimators was set to 10 cm
x 10 cm. A mechanical front pointer was used to set the water surface to 100 cm from the
source. The CC13 chamber was aligned to the central axis of the field. The gantry was
then rotated 90 ◦ so the XI head unit was positioned above the tank. The blade openings
of the XI were set to 10 cm x 10 cm. The field sizes for both the XI and the Truebeam
treatment head are defined at 100 cm from the source. The bowtie and beam hardening
filter were removed from the field.
Surface measurements for the PDDs were performed at the depth of the chamber radius
(3 mm).4,21 Measurements were performed in 2 mm increments for the first five points,
after which 10 mm increments were used. PDDs were also measured for the beam ar-
rangements used for CBCT imaging. The scanning parameters are shown in table 4.1.
Profile measurements were performed in a Blue Phantom 2 (IBA Group) 3D scanning
(3DS) water tank (figure 4.2c). The tank is usually on a mechanical platform and can be
adjusted to ensure the water level is aligned with the direction of chamber travel. Due to
the inability to retract the XI detector panel while an x-ray beam is being produced the
3DS tank could not be wheeled in on its platform. Instead it was placed on the IGRT
couch. The weight of the tank and the water on the couch could not exceed 100 kg.
Due to this weight restriction the tank was filled to a depth of 10 cm. Because of this
limitation PDDs could not be measured in the 3DS tank.
The water surface was positioned 100 cm from the x-ray tube focal spot. The XI source
unit was positioned above the water tank (gantry at 90◦). Static beam acquisitions were
performed using the blade openings as seen in figure 4.5. The method used for imaging
beam data acquisition is given by Ding et al.17 Using the scanning parameters seen in
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Figure 4.1: 10 cm x 10 cm depth doses and profiles were measured in the 1D scanning
tank to verify the simulated x-ray spectra.
table 4.1 measurements were taken for 4 seconds per point. Profiles were measured with
a resolution of 4 mm. Ionisation data was not converted into dose for relative dosimetry
measurements. Profile measurements were performed with and without bowtie filters in
place.
4.1.1 Results
Running simulations for 1×109 primary photons took 15 hours using the 8 core processor
system. The simulated results were compared against experimental measurements. For
the simulated results the statistical uncertainty was <1% at the point of normalisation.
Experimental and simulated PDDs compared in a 10 cm x 10 cm field matched within
3% (figure 4.1). This comparison was the intial indication that the simulated spectra had
been correctly modelled. PDDs and profiles for the head and body scanning protocols
were compared at the reference depth, 2 cm (figure 4.3 and 4.4). Simulated and experi-
mental PDD measurements showed good agreement and matched within 3%. Simulated
and experimentally measured profiles matched within 10%.
Figure 4.7 shows the simulated and experimental x-axis profiles at 1 cm and 5 cm depths
for the head scan protocol.
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(a) 1DS water tank (b) Field and reference detectors
(c) 3DS water tank
Figure 4.2: Relative dosimetry was performed in two water-filled phantoms. Percentage
depth doses (PDD) were measured using a 1D scanning water tank. Profiles were mea-
sured in a 3D scanning (3DS) water tank. The 3DS tank was placed on the treatment
couch so it did not collide with the XI detector when the gantry was rotated. The 3DS
tank could be filled to a maximum depth of 8 cm due to the weight restrictions on the
treatment couch.
62
4.2 Absolute dose calibration
Figure 4.3: A comparison of simulated and measured depth doses for CBCT imaging
protocols. Experimental measurements were performed in 2 mm increments until reaching
a depth of 10 mm. After this 10 mm increments were used.
4.2 Absolute dose calibration
Dose calculations in GATE were matched with experimental measurements to assess their
ability to model the relative dosimetry of dose deposition. The next step was to convert
the GATE dose calculations into absorbed dose. To convert the calculations reference
dosimetry measurements were performed
Half value layer
Narrowbeam geometry conditions were used to measure the first HVL of the 100 kVp
and 125 kVp beam. This is the recommendation of AAPM TG-61. Narrowbeam geom-
etry involves 4 components: an x-ray source, collimation, attenuating material, and an
appropriate detector. A typical setup is pictured in Figure 4.8. An in-house acrylic jig
was used to perform the HVL measurements. The jig can be seen in Figure 4.9a. A lead
diaphragm was used to collimate the x-ray beam. the diaphragm was positioned 72.5 cm
from the x-ray source. The collimator opening was a 3 cm diameter circle. Aluminium
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Figure 4.4: Comparison between GATE and experimental measurement dosimetric pro-
files. Comparisons are made with and without the bowtie filter. Profiles were measured
at 2 cm depth. For x-axis profiles: X2 is in the negative direction and X1 is in the pos-
itive direction. For y-axis profiles: Y1 is in the negative (anode) direction and Y2 is in
the positive (cathode) direction. All the experimental profiles have been re-sampled for
clarity.
was used to attenuate the beam. The thickness of aluminium sheets used was 0.25 mm,
0.5 mm and 1.0 mm. The sheets were fixed in place against the lead diaphragm using two
screws. The given purity was 99.9%. An FC65-G farmer-type ionisation chamber was
used to measure air kerma rate. It was fixed roughly 50 cm from the diaphragm. As per
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(a) Head scan protocol (b) Body scan protocol
Figure 4.5: The figure above illustrates the collimator positions used for CBCT imaging.
The field sizes are defined at a distance 100 cm from the source. The imaged object
sits between the source and the flat panel detector. The head scan protocol is used for
smaller objects. The entire object is in the imaging field. During the body scan protocl
the detector panel is shifted in the x1 direction. The X1 blade opening is increased to
24.7 cm while the X2 blade opening is reduced to 3.4 cm.
TG-61 requirements the chamber has an energy dependent response less than 5% over a
tube potential range of 40 kV to 300 kV.
The ionisation chamber and source were aligned down the central axis of the x-ray beam.
This was achieved using an external laser system (Figure 4.9b). To confirm the correct
positioning of the chamber sensitive volume and anode XR-QA2 radiochromic film was
placed behind the chamber. The film was exposed under the x-ray beam. The position
of the chamber’s sensitive volume and anode can be seen in figure 4.9c.
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Figure 4.6: The heel effect decreases the intensity of an x-ray beam towards the anode
side of the beam. X-rays emitted perpendicular to the anode-cathode axis will travel
through a longer length of anode compared to those emitted perpendicular to the face of
the anode (i.e. intensity IA is less than intensity IB)
Figure 4.7: Comparison between GATE simulated and experimental results for profiles
at 1 cm and 5 cm depth using the head scan beam configuration.
66
4.2 Absolute dose calibration
Figure 4.8: A narrowbeam geometry setup for HVL measurement. Included is the rec-
ommended spacing between the source, diaphragm, and ionisation chamber.
The exposures performed used 500 mAs and a 2x2 cm2 field size (defined at isocentre). The
beam hardening filter was used. Measurements were performed both with and without
bowtie filters in field.
A stable kerma rate was measured from the unattenuated beam. Aluminium sheets were
introduced incrementally. Measurements were performed until a sufficient aluminium was
introduced to reduce the kerma rate below 50%.
The Black Piranha 455 CT Profiler (RTI Group, Mölndal, Sweden) was used to compare
to the narrowbeam geometry values. The piranha can be used to measure a beam HVL
in a single exposure without collimation or filtration. It is much less sensitive to scattered
radiation than a typical farmer-type ion chamber.84
The detector was placed on the IGRT couch at 100 cm SSD. The field sizes used at 100
cm SSD were 4x4 cm2 and 8x8 cm2. The XI source was positioned above the detector.
A continuous pulsed beam was delivered to the detector and a stable value was recorded.
Varying the mAs of the pulsed beam had no effect on the recorded values.
4.2.1 TLD calibration
TLDs should be calibrated in the beam quality under investigation in attempts to elim-
inate any uncertainty in energy dependence. A batch of TLD-100 chip dosimeters (Har-
shaw, type TLD-100, Thermo Fisher Scientific Inc., Waltham, MA) were calibrated for
both beam energies studied. There were 13 TLDs in each batch. 6 TLD pairs per energy
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(a)
(b) (c)
Figure 4.9: The setup used to measure beam quality. (a) A one meter long jig for
measuring HVLs was used to determine the x-ray tube beam quality (b) external laser
(c) radiochromic film
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with a spare in each. A standard TLD readout protocol was performed using an auto-
mated TLD reader with hot nitrogen heating (Harshaw 5500; Thermo Fisher Scientific
Inc.). The TLDs were read out at least an hour after being exposed. Before readout the
TLDs are pre-annealed at 165◦C. Then constant heating to a maximum temperature of
270◦C is applied. This temperature is used to exceed all glow peak positions for TLD-100
dosimeters.
(a) (b)
Figure 4.10: The experimental setup used for determining TLD-100 sensitivty correction
factors
TLD sensitivity
The sensitivity correction factors (SCF) were measured for both batches of TLDs. The
factor requires TLD response to be based on identical reference conditions. An entire
batch of TLDs is not able to be irradiated at the same point in a beam at the same time.
To measure all TLDs under the same beam they had to be evenly offset from the central
axis. The beam from an x-ray tube is not uniform across its profile. To ensure a uniform
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exposure to all the TLDs in a batch they were rotated around the central axis of the beam
at a fixed distance. A turntable (Figure 4.10a) was used to provide uniform exposure to
the TLDs. An acrylic TLD phantom (Figure 4.10b) was placed on the turntable’s rotating
stage on top of an additional 5 cm of acrylic. The phantom is 2 cm thick and consists of
50 shallow-drilled holes spaced evenly in a 16 cm diameter circle. The TLDs were placed
in the first 13 holes in the phantom. The phantom was aligned with the central axis of
the x-ray beam. A mylar film was placed over top of the phantom. the source-to-surface
distance was set to 100 cm. The phantom was rotated at 35 rpm. A total exposure of
1000 mAs was delivered for both 100 kV and 125 kV photon beams. A 50 x 50 cm2 field
size was set at the phantom surface. Only the beam hardening filtration was used for this
measurement. The TLDs were readout and annealed following the procedure detailed
above. Each batch was irradiated five times.
(a) (b)
Figure 4.11: The experimental setup used for determining TLD batch calibration factor,
ND,w
Determining TLD calibration factors
Each batch of TLDs was cross calibrated with a 0.65 cm3 FC65-G (IBA Group, Louvain-
La-Neuve, Belgium) farmer-type ionisation chamber. This was done to derive a batch
conversion factor Nw,batch, for both beam qualities used. The ionisation chamber had
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been calibrated in terms of air kerma at a primary standards dosimetry laboratory. The
absorbed dose was measured using the AAPM TG-61 reference dosimetry protocol. To
perform the cross calibration with TLDs an in-phantom measurement was performed.
The measurement conditions for the experiment are given in Table 4.2.
An in-house acrylic water phantom was used to perform the cross calibration measure-
ments (Figure 4.11a). The phantom includes a 3 mm thick acrylic waterproofing sleeve.
A farmer-type ionisation chamber can be inserted into this sleeve. A TLD holder had
also been designed to fit in the waterproof acrylic sleeve (figure 4.11b). The acrylic TLD
holder can have up to 4 TLD-100 detectors placed into a recessed holding space. The
position of the TLDs coincides with the sensitive volume of a Farmer-type chamber. An
acrylic cover is placed over top of the TLDs to eliminate movement.
Four TLD chips were selected at random for both beam qualities. TLD exposures were
performed directly after ion chamber measurements. A small amount of water was added
to the tank to account for the 1.25 mm elevated active area of the TLD-100 detectors.
Table 4.2: Reference conditions used for in-phantom absorbed dose to water for the
Truebeam XI system. Both the FC65-G Farmer-type ionisation chamber and TLD-100
detectors were exposed under the same conditions.
Reference condition
Phantom material Water
Chamber type Farmer-type chamber (FC65-G)
Waterproofing 3 mm acrylic
Measurement depth 2 cm
SSD 100 cm
Field size at 100 cm 10 x 10 cm2
Total exposure 1000 mAs
Filtration Beam hardening and Bowtie
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(a) Head phantom (b) Pelvis phantom
Figure 4.12: The RANDO phantom is an anthropomorphic phantom that can be used
for the direct measurement of absorbed dose. The phantom is made up of 34 2.5 cm
transverse sections. The CT images above show the individual sections of the phantom
used in this study. These images were imported into GATE for dose comparison with
physical measurements. The crosshairs are aligned to the isocentre of the scan.
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4.2.2 Anthropomorphic phantom study
The Rando phantom (Radiation analog dosimetry system: Nuclear Associates, Hicksville,
NY) was used to carry out a TLD dose study. The Rando phantom is an anthropomorphic
male phantom. It is formed by a skeleton encased in a rubber material with radiological
properties of near equivalence to soft tissue.85 The phantom is shown in Figure ??. The
phantom is divided into 34 2.5 cm sections. These sections have cylindrical orifices which
TLDs are placed within.
The phantom replicates a human anatomy from the top of the head to part way through
the femoral bones. The volumes of the phantom used in this study were the head and
pelvis. The head phantom includes the the portion of the phantom from the neck region
and up (Figure 4.12a. The pelvis phantom covers the region of anatomy from the ilium
to part way through the femurs (Figure 4.12b.
Firstly tomographic images of the phantom were acquired using a Toshiba CT scanner.
The beam width used during CT acquisition was 1 mm for the rando head phantom and
2 mm for the pelvis phantom. The voxel size was 0.5 x 0.5 x 1 mm for the head phantom
and 0.8 x 0.8 x 2 mm for the pelvis phantom. Both image sets were imported into the
Varian Eclipse work station. TLD positions were contoured on the image set and the
DICOM origin position was set to the isocentre of the scanning volume. The image sets
were suitably free of artifacts.
The TLD-100 chip dosimeters were placed in the positions seen in Figure 4.13 for both
head and pelvis phantoms. The TLDs measure 3 x 3 x 1 mm. Their size allows them to
be placed in the orifices in the RANDO phantom. TLDs were irradiated in pairs in order
to control for any unexpected variations in single TLD readings. Air gaps were filled with
rubber plugs.
The phantoms with embedded TLDs were transferred to the treatment couch and the
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(a) Head phantom
(b) Pelvis phantom
Figure 4.13: TLD dose measurement locations for the RANDO phantom (red text). Three
sections of the head phantom were used for TLD measurements. Only one section of the
pelvis phantom was used due to the higher number of orifices for TLD placement.
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setup from CT imaging was replicated using marks that had been placed on the phantom
in the saggital, transverse, and coronal planes. When the machine isocentre was matched
with the phantom isocentre the imaging protocol was delivered. The scanning parameters
used for scanning of the head and body phantom are shown in table 4.1.
4.2.3 Simulation in GATE
GATE has the ability to import medical image data or STL files to construct voxelised
phantoms. Metaimage files are a medical image file format that are compatible with
GATE. Metaimage data retains DICOM coordinates and properties important to anatom-
ical representation. It has the advantage over DICOM and STL data of being a stable
image.
The DICOM image studies of the RANDO phantom were converted into metaimage files
and imported into GATE. Dose actors were attached to the volumes. The resolutions used
for the voxelised grids were set to match voxel size of each image study (given above).
The output file from the dose grid set to metaimage file to retain the isocentre position
used in the simulation. Image grayscales were converted into material definitions using
values given from a study by Schneider et al.86
After the GATE simulation was complete the metaimage dose grids were simulated in
GATE for the two phantoms. The MetaImage dose grid was imported into ImageJ. TLD
positions that had been contoured in Eclipse were converted to .roi files that are read into
ImageJ’s ”ROI manager”. The dose for each TLD position.
4.2.4 Results
AAPM TG-61 Reference dosimetry for XI CBCT
The HVLs measured for both beam configurations are given in table 4.3. The 125 kVp,
half bowtie filter configuration and 100 kVp, full bowtie filter configuration had a HVL
of 8.3 mm Al. The 100 kVp, full bowtie filter configuration had an HVL of 7.1 mm Al.
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Direct measurements of HVL resulted in an increase of 0.3 mm Al in these values. The
increase was assumed to be attributed to back-scatter from the detector panel and the
values were discarded.
Reference dosimetry was performed for both the filtered 100 kVp and 125 kVp spectra.
Reference conditions are specified in table 4.2. Using the AAPM TG-61 absorbed dose to
water protocol at 2 cm depth the dose rate was found to be 90 µGy/mAs and 50 µGy/mAs
for the 125 kVp and 100 kVp beams, respectively. The ion chamber measurements were
reproducible within 0.2%. A worksheet for for TG-61 reference dosimetry is included in
Appendix A.1.
Cross-calibration of point dose to TLDs
TLDs were calibrated under the reference conditions used in table 4.2. From this mea-
surement calibration factors were calculated to convert TLD dose response into absolute
dose. Calibration factors of 0.16 mGy/nC and 0.19 mGy/nC were given for the 125 kVp
and 100 kVp beams, respectively. The derivation of TLD calibration factors is shown in
appendix Figure C.2.
The TLD dose linearity was assessed over a range of exposures from 10 mAs to 1000 mAs.
The TLD measured dose against exposure is given in figure 4.14.
Table 4.3: Half value layer (HVL) was measured using the Pirahna CT dose profiler
(CTDP). The corresponding air-kerma calibration factor is also given
Tube potential (kVp) Bowtie filter HVL (mm Al) Calibration factor, Nk (mGy/nC)
125 Half 8.34 44.95
100 Full 7.12 45.02
Monte Carlo calibration factors
Simulated and experimental results were gathered in the RANDO anthropomorphic phan-
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Figure 4.14: TLD dose linearity over the exposure range 10 mAs - 1000 mAs
tom. The statistical uncertainty for MC simulated doses in RANDO was less than 2.5%
at all measured points (for 2 × 107 total primaries). Calibration factors were calculated
to convert simulated results into valid experimental results. For the head scan protocol
(100 kVp, 7.1 mm Al) the calibration factor was 2.46× 1011 ± 1.02× 1010 photons/mAs.
For the body scan protocol (125 kVp, 8.3 mm Al) the average calibration factor was
4.29× 1011 ± 1.26× 1010 photons/mAs.
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Table 4.4: Comparison between measured and simulated doses for both pelvis and head
phantoms. Figure 4.13 can be used as a reference for the TLD positions. The doses are
reported in dose to water
Location TLD (mGy) GATE (mGy) Difference
Pelvis scan
Right femoral head (P1) 15.2±1.0 24.9±0.3 48.5%
Left Ischial Spine (P2) 17.5±1.2 16.9 ±0.9 -3.5%
Left femoral head (P3) 19.8±1.0 21.4 ±0.5 8.2%
Right femoral artery (P4) 24.7±1.3 25.4 ±0.3 -3.2%
Sacrum (P5) 25.4±1.3 25.3 ±0.3 0.0%
Centre (P6) 25.3±1.3 20.9 ±0.4 -18.7%
Head scan
Superior (H1) 3.1± 0.2 2.8± < 0.1 -9.2%
Inferior (H2) 3.1± 0.2 3.5± < 0.1 10.1%
Right (H3) 2.8± 0.2 2.9± < 0.1 3.2%
Left (H4) 3.2± 0.2 3.1± < 0.1 -3.1%
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Cone-beam CT technology is widely deployed throughout radiation therapy clinics world-
wide. There are numerous studies evaluating indirect measures of dose for these scanners.
Patient dosimetry, however, makes up a small portion of CBCT dose studies and scan-
ners, such as the XI, have limited information on the absorbed dose received by patients
from their use. In this chapter the ICRP computational phantom is imported into the
GATE simulation environment to preform dose calculations. The data gathered is used to
evaluate the effective dose and to construct dose-volume histograms from CBCT imaging
procedures.
(a) Frontal view (b) Saggital view
Figure 5.1: The ICRP computational phantom is an aggregated anthropomorphic phan-
tom from the medical imaging data of real people. The organs are consistent with anatom-
ical data given by ICRP report 89.
79
5 CBCT population dose analysis
5.1 Method
The ICRP phantom was imported into GATE. The ICRP phantom is a 27.14 cm x 54.28
cm x 177.6 cm (127 x 254 x 222 pixels) volume. The ’ImageNestParameterised’ navigation
algorithm option was used to translate the phantom in the phantom volume.
CBCT imaging dose were investigated for six common radiation treatment sites:
• Head imaging protocol. 2 sites: Brain and larynx.
• Thorax imaging protocol. 3 sites: Mid-lung, left lung, and right lung.
• Pelvis imaging protocol. 1 site: Prostate.
For each site the ICRP phantom was translated so the anatomy aligned with the isocen-
tre of the model. Simulations were performed using both clockwise and counterclockwise
acquisitions. For head and neck scanning, which involves a 200 degree scanning arc, a
counter clockwise rotation from 90◦ and 250◦ was used.
The seTLE dose actor was applied to the phantom volume. The resolution of the dose
actor was set to 0.21 x 0.21 x 0.8 cm to match the resolution of the image set. The primary
multiplicity factor was set to 200 and the secondary multiplicity was set to 400. These
values were chosen to provide the optimal primary dose vs secondary dose distribution
ratios.76 The total number of primaries generated was 1× 107
The calibration factors determined in the previous chapter were used to convert the simu-
lated doses to absorbed dose. As pelvis and thorax imaging protocols use the same beam
energy, bowtie filter, and collimation, the same calibration factor was used. The simulated
doses were divided by the total number of primaries simulated and then multiplied by the
total exposure (mAs) and dose calibration factor.
The metaimage dose grids were analysed in imageJ. The ICRP phantom organs were
contoured using the inbuilt region of interest (ROI) manager. DVHs were constructed
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using a combination of the ROI manager and inbuilt thresholding tools in imageJ.
5.2 Results
5.2.1 Effective dose
(a) Head and neck
(b) Thorax (c) Pelvis
Figure 5.2: Simulated dose distribution grids for the three XI imaging protocols. Doses
are given in mGy.
Simulating dose grids for CBCT imaging protocols took between 67 and 84 hours using
the Intel 8 core processor. Organ doses and effective doses were simulated for each XI
scan procedure. The results are seen in table 5.1. Organ doses are given as average values
over the entire organ volume. Repeat simulations showed that total effective doses were
reproducible within 1%.
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The highest effective dose was calculated for pelvis imaging. The effective dose was
3.91±0.11 mSv when the prostate was at the isocentre of the scan. The highest average
organ doses were received by the gonads (24.6 mGy) and the bladder (19.4 mGy). Whole
body organs such as bone marrow, bone, and skin received average doses of 3.0 mGy, 7.8
mGy, and 1.87 mGy. The maximum doses of these structures 40.2 mGy, 94.6 mGy and
30.8 mGy (table 5.2).
Thorax imaging had an effective dose of 1.72±0.07 mSv (lung centre at isocentre). The
highest average organ dose was received by bone (6.2 mGy). Lung, breast, and thyroid
received average doses of 3.2 mGy, 3.2 mGy, and 3.4 mGy. The average skin and bone
marrow doses were 0.5 mGy and 1.6 mGy. Maximum doses for bone marrow, bone sur-
face, and skin were 12.4 mGy, 30.1 mGy, and 8.2 mGy.
Head imaging had an effective dose of 0.289±0.020 mSv (brain at isocentre). The highest
average organ dose was recieved by the salivary glands (3.9 mGy) and brain (2.3 mGy).
Whole body organs such as bone marrow, bone, and skin received average doses of 0.6
mGy, 1.1 mGy, and 0.5 mGy. Maximum doses for these organs were 14.1 mGy, 18.3 mGy,
and 7.8 mGy, respectively.
The effective dose for all six scans centres analysed are summarised in table 5.3.
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Table 5.1: Organ and effective doses simulated for XI scan protocols. Head scans were
performed between gantry angles 270◦ and 110◦
Head Thorax Pelvis
Tube voltage (kVp) 100 125 125
Tube current (mA) 15 15 60
Pulse duration (ms) 20 20 20
Exposure (mAs) 147 264 1074
Scan arc (deg) 200 360 360
Organ dose (mGy)
Bone marrow 0.616 1.57 2.96
Colon 0.00978 0.260 2.96
Lung 0.0627 3.24 0.0690
Stomach 0.0175 1.67 0.156
Breast 0.0402 3.19 0.0858
Gonads 0.00507 0.0135 24.6
Bladder 0.00405 0.0174 19.4
Oesophagus 0.436 2.75 0.0484
Liver 0.0168 1.85 0.182
Thyroid 0.658 3.42 0.0506
Bone surface 1.10 6.21 7.84
Brain 2.33 0.0422 0.0302
Salivary glands 3.89 0.297 0.0466
Skin 0.474 0.466 1.87
Remaining tissues* 0.639 1.17 2.05
Total effective dose (mSv) 0.289 ± 0.020 1.72 ± 0.07 3.91 ± 0.11
*adrenals, extrathoracic region, gall bladder, heart, kidneys, lymphatic nodes, muscle,
oral mucosa, pancreas, prostate, small intenstine, spleen, thymus
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Table 5.2: Simulated average and maximum organ doses for XI scan protocols. Critical
structures for each site are included as well as the dose to whole body organs (i.e. skin,
bone, bone marrow)




Left eye 5.6 6.3
Right eye 5.4 6.1
Left lens 5.9 6.0
Right lens 6.1 6.2
Skin 0.5 7.8
Bone 1.1 18.3
Bone marrow 0.6 14.1
Thorax
Isocentre 5.1 -
Left lung 2.5 5.4
Right lung 4.0 6.4
Spinal cord 1.4 2.9
Skin 1.1 7.6
Bone 6.3 30.6








Bone marrow 2.9 40.2
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Table 5.3: A summary of the effective doses for the scan protocols and imaging centres
examined in this study.
Scan protocol Scan centre Total effective
dose (mSv)
Head Brain 0.29 ± 0.02
Larynx 0.89 ± 0.04
Thorax Mid-lung 1.72 ± 0.08
Left lung 2.03 ± 0.09
Right lung 1.53 ± 0.07
Pelvis Prostate 3.91 ± 0.11
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5.2.2 Treatment planning doses
Dose volume histograms were calculated for CBCT imaging. The DVHs are reported for
organs at risk and are based on scan protocol and isocentre location. The DVHs for three
scan protocols and six scanning isocentres can be seen in figures 5.3, 5.4, and 5.5. D50%
and D10% metrics are given for the major planning organs at risk and target structures for
each anatomical site. D50% and D10% are the minimum dose delivered to 50% and 10% of
the organ volume, respectively.
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Spinal cord 1.87 2.17
Right eye 5.66 5.96




(b) Brain scan dose statistics






Spinal cord 2.12 3.13
Oral cavity 2.56 3.98
Left parotid 4.11 4.39
Brain 0.33 0.78
Skin 0.51 5.33
Right parotid 4.03 4.36
Oral cavity 2.55 3.94
(d) Larynx scan dose statistics
Figure 5.3: Dose-volume histograms (DVHs) (a,c) and tabulated dose metrics (b,d) for
radiosensitive organs from XI CBCT imaging. (a,b) Head CBCT imaging is performed
with the brain at the isocentre. (c,d) Head CBCT imaging is performed with the larynx
at the isocentre
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Right lung 2.49 3.77
Left lung 5.08 6.10
Spinal cord 1.34 1.99
Skin 2.88 6.10
(b) Left lung scan dose statistics






Right lung 3.89 5.27
Left lung 2.22 3.59
Spinal cord 1.70 2.48
Skin 0.285 3.62
(d) Mid-lung scan dose statistics
Figure 5.4: Dose-volume histograms (DVHs) (a,c) and tabulated dose metrics (b,d) for
radiosensitive organs from XI CBCT imaging. (a,b) Thorax CBCT imaging is performed
with the left lung at the isocentre. (c,d) Thorax CBCT imaging is performed with the
mid-lung at the isocentre
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Right lung 4.51 5.22
Left lung 1.97 2.63
Spinal cord 1.64 2.82
Skin 2.52 4.73











(d) Prostate scan dose statistics
Figure 5.5: Dose-volume histograms (DVHs) (a,c) and tabulated dose metrics (b,d) for
radiosensitive organs from XI CBCT imaging. (a,b) Thorax CBCT imaging is performed
with the right lung at the isocentre. (c,d) Pelvis CBCT imaging is performed with the
prostate at the isocentre
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There have been several studies carried out to quantify dosimetry from CBCT imag-
ing.17,37,40 These studies report on a variety of direct and indirect measures to quantify
dose from different CBCT scanners.30,33,57,74,87,88
This thesis work uses Monte Carlo (MC) methods to quantify patient dosimetry from
CBCT imaging using the Varian XI scanner. As of this work, there is a scarce amount
of directly measured dosimetry data available for this scanner.31,58 Additionally, no stud-
ies have evaluated organ dose-volume histograms for the scan protocols used by the XI
system.
6.1 Validation and calibration of the GATE CBCT model
Validation of the MC model started with verifying the x-ray spectra simulated. X-ray
spectra were simulated in GATE by modelling the GS-1542 x-ray tube according to man-
ufacturer documents. 2.7 mm aluminium filtration was applied to the tube to simulate
the spectra. The initial validation was provided by matching simulated and experimental
depth dose results, with no additional filtration, in a 10 cm x 10 cm field (figure 4.1). The
agreement in these PDDs was 3%. Once PDDs were verified with no additional filtration,
simulations were performed for the Varian XI scan protocols.
The method used for simulating and validating x-ray spectra did not provide consistent
accuracy for both beam models. The full experimental validation results show that the
spectrum simulated for the 125 kVp beam model was more accurate than the 100 kVp beam
model. Both relative dosimetry and absolute dosimetry measurements yielded better
agreement with the 125 kVp spectra.
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6.1.1 Relative dosimetry
Relative dosimetry comparisons were made between simulated and experimental results.
For the scan protocols examined comparison of PDDs showed good agreement and matched
within 2% for the differing field sizes and filtration conditions examined.
Simulated and experimental profiles matched within 10% of each other. It is seen in figure
4.4 that the best match is seen in the x-axis with no bowtie filter in place. These profiles
match within 4% (outside of the penumbra region). When the bowtie filter is added re-
sults match within 4% for the body scan protocol and 10% for the head scan protocol.
In figure 4.4 it is shown that the experimentally measured profiles in the Y-axis dis-
play an asymmetry across the direction of the beam measurement. The measured profile
shows higher deposition towards the cathode side of the profile. This trend is due to
self-attenuation in the anode or the ”heel effect”. The heel effect occurs due to the in-
creased travel length through the anode material for photons emitted towards the anode
side of the tube (figure 4.6). Increasing travel distance through the tungsten anode leads
to greater probability of photon attenuation. This results in an x-ray beam with less
intensity towards anode side of the x-ray tube. The simulated results do not replicate
the heel effect. The voxelised source input in GATE does not allow the modelling of this
intensity distribution across the source.
Marchant and Joshi proposed a method for modelling the heel effect using a voxelised
source input.40 Their method involved generating a tungsten medium in their simulation
and positioning the source below the surface of the anode. The source is placed at the
mean depth of interaction (which is a few microns deep). From there the source can be
rotated to replicate the differential travel path length of x-rays generated in the anode.
Problematically, this will modify the energy distribution the of x-ray spectrum due to
attenuation in the anode. It will also reduce simulation efficiencies from extra CPU time
spent tracking photons inside the anode volume.
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It was decided that as the experimental and simulated y-axis profiles matched within
10%, comparable to the x-axis profiles, no further action would be taken to model the
heel effect. To simulate the heel effect for future work it is recommended that a phase
space type file should be used instead of the voxelised source input.
6.1.2 Absolute dose calibration
6.1.2.1 TLD Rando study
TLDs were calibrated under 100 kVp and 125 kVp beams at a point 2 cm deep in water.
The TLDs were placed in the anthropomorphic head and pelvis RANDO phantom. The
measured doses varied between 15.5 mGy and 25.3 mGy
A study conducted by Hauri et al. examined pelvic imaging doses from the XI system in
the RANDO phantom.58 Their findings show good agreement with the ones found in this
study. The mean dose from found from 37 in-field measurements was 20.5 mGy±5% in
Hauri et al. compared to 21.3 mGy±3% in this study. This study measured these values
based on 6 points.
The response of the TLDs was corrected only for batch sensitivity and energy dependent
calibration. The response of the TLDs were not depth corrected. Studies have shown
there is expected to be a variation in TLD response with depth.89,90 A study by Mail et
al. introduce a correction factor that compensates the response of luminescent dosimeters
at depth.89 The depth correction factor was given as a ratio of the dose measured by
ionisation chamber to that of the uncorrected dosimeter as a function of depth. The ratio
varied TLD response by a maximum of 2%. The energy response of TLDs at depth was
not considered on the TLD study conducted in this work. This could be incorporated
into future work. Another study found that spectral changes at depths between 1 cm and
10 cm under a 6 MV beam resulted in an 8.5 % variation in energy correction factors.
92
6.1 Validation and calibration of the GATE CBCT model
6.1.2.2 Monte Carlo calibration factor
The CT image studies for both phantoms were imported into GATE. Dose distributions
were simulated for both phantoms. On the simulated dose grid measurements were per-
formed at the TLD locations shown in figure 4.13. A calibration factor was applied to the
simulated doses to analyse the suitability of the factor. The calibrated simulated results
and TLD measurements showed expected agreement (Table 4.4). The average difference
with experimental measurements was 13.7% for pelvis CBCT and 6.4% for head CBCT.
The maximum difference for both protocols was 48.5% and 10.1%, respectively.
From table 4.4 it can be seen the simulated result at point P1 in the pelvis phantom
showed a large difference with its corresponding experimental value. The simulated dose
was 48.5% higher than its corresponding experimental measurement. This difference is
due to the HU value from the CT image. TLD measuremenets were performed at Point
P1 was measured in the femoral spongiosa. The surrounding bony anatomy resulted in
an increased HU value at this point which changed the material conversion applied when
using the Schneider conversion table. The remaining TLD location There are limitations
in using grayscale to material definition conversions. grayscale value for a given material
can vary depending on the CT system used and how a scan is parameterised. Segmentation
of the RANDO phantom may have ensured more consistency in the grayscale conversion
for the specified materials.85
The biggest discrepancy for the pelvis phantom comparison was in the measurement at
the centre of the phantom. The calibrated MC dose underestimated the dose to this point
by -25.1%. It is thought that this is due to a weighting bias in determining the calibration
factor in this study. From observing figure 4.13b.
For the head phantom measurements the largest discrepancy is seen for TLD measure-
ments in the inferior and superior portions of the phantom. This is due to the absence
of the heel effect in the simulated dose distribution (see y-axis profiles in figure 4.4). The
superior and inferior measurements are separated in the y-axis of the imaging field. In
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the superior position the TLD dose is underestimated 9.2% by the simulated result. In
the inferior portion of the beam it is overestimated 10.1% by the simulated result.
Using relative benchmarks for absolute calibration is not as robust as an absolute com-
parison. The relative benchmark measurements used here are made worse by the use of
TLD detectors. Repeat TLD-100 measurements typically vary between 2% and 10%.25
By performing 3 to 4 measurements the type A uncertainty did not exceed 5%. The total
combined uncertainty did not exceed 10% for any of the measurements. The influence
quantities for the combined uncertainty evaluation are seen in Appendix ??.
There was a limited number of TLD-100 dosimeters available for use in this study as
many were also required for clinical use. The number of sites measured was acceptable
for evaluating the dose due to imaging but insufficient for calibrating a MC beam model.
By increasing the number of measurement sites a MC calibration factor could be more
accurately determined. To improve the calculation of the MC calibration factor it is
recommended that more measurement locations be used both in-field and out-of-field.
6.2 Population dose calculations
There are three CBCT image acquisition modes used by the XI scanner. This study
examines the dosimetry for all three imaging modes. The ICRP phantom was used to
provide a computational phantom that is anatomically representative of a cohort of ra-
diation therapy patients. The organs in the phantom are consistent with the anatomical
parameters given in ICRP report 89 allowing the analysis of organ and effective dose.91
6.2.1 Organ dose and effective dose
The effective dose is a weighted risk estimate for low dose procedures. The absorbed
dose received by a number of organs around the body are weighted. The limitation of
scoring dose in out-of-field organs should be considered. Due to low photon scoring in
these organs the uncertainty in their dose measurement is higher than doses scored in the
scanning field. The uncertainties in each organ are factored in to the combined uncer-
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tainty for the effective dose.
Organ and effective doses were calculated using the ICRP phantom dose grids. The re-
sults in table 5.1 are comparable to those found in a study by Pyone et al. (table 2.1). In
their study they used the ImPACT CT dosimetry software to calculate effective doses for
the three XI CBCT protocols. For the head, thorax and scan protocols they calculated
total effective doses of 0.1 mSv, 2.4 mSv, and 4.9 mSv. The ImPACT software calculates
organ and effective doses that are higher than those dound in this study for the head
CBCT imaging protocol. the difference between the ImPACT calculator and MC lower
than those found by MC methods here. The difference in effective dose for head, thorax,
and pelvis CBCT imaging is -65.4%, -14.0% and -10.5%, respectively. This appears to
agree with the observation made in chapter 4 regarding excessive beam hardening of the
spectra from the beam model. It must also be noted that the ImPACT software calculates
non-isocentre specific organ doses from CTDI measurments and therefore a true compar-
ison is difficult to establish.
The effective dose calculated by Hauri et al. shows good agreement with the doses calcu-
lated here. Only the dose received by the gonads was estimated due to the limitations of
available measurement points in their RANDO phantom. Although their study arrived
at the same calculated effective dose there are a number of discrepancies between the
absorbed doses measured in their work and this study.
The measured skin dose in Hauri et al. greatly exceeds the one calculated in this study.
The skin dose measured for pelvis scanning in their study is 458% higher than the calcu-
lated dose in this study. The difference in skin dose is due to two factors. Firstly, only
5 measurement points were taken for the whole body skin dose in Hauri et al. This will
skew the dose response towards teh dose response in the in-field measurements. TLDs
have been used in many radiation therapy studies and are known to
Effective dose for evaluating radiation-induced cancer risk for low doses is a useful de-
scriptor. Especially in the case that there is no available epidemiology studies. However,
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it is important to not put too much emphasis on effective dose values as they are intended
as a rough estimate of dose detriment for patients. The radiation and tissue weighting
factors are based on current, limited understanding of radiation risks. They are simple
values with large uncertainties associated. For example, using the radiation weighting
factor for x-rays a given organ dose from a 100 kV and a 6 MV source would be weighted
equally for biological damage. Tissue weighting factors are age- and sex-averaged values
that do not reflect the likelihood of cancer development in different subjects, regardless
of age or gender. A study on the uncertainties in effective dose calculation was preformed
by Martin.92 In his studies experimental, empirical, and Monte Carlo methods for de-
termining effective dose. The study finds that for a given phantom the uncertainties in
calculating effective dose can reach 40%.
It is important to note that organ and tissue radiobiological sensitivities are not consistent
with age and gender. It is desirable that weighting factors set by the ICRP can be used
dose-risk correlation for patients of differing age and gender.
These scans are not isocentre specific. In a study by Martin the uncertainties associated
with effective dose calculation are analysed. The study finds that even for population-
based phantoms uncertainties in calculating effective dose may reach 40%.92
Effective dose calculations are heavily weighted towards the thorax region of human
anatomy. There are many structures in this region that the effective dose is calculated
for. Therefore accurate dose scoring in the thoraz region will provide a better estimate of
effective dose. Due to the absence of the heel effect in the beam model the effective doses
calculated varied for out-of-field organs. For the head scanning protocol, the simulated
results overestimated the absorbded dose to organs in the inferior portion of the phantom,
lead to an overall increase in effective dose. For pelvis CBCT imaging the absorbed doses
to superior organs were underestimated, resulting in a smaller value for effective dose.
Thorax CBCT imaging is the least biased by not modelling the heel effect in the beam
model.
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Offset in scan centre had a small impact on effective dose. The uncertainty is lower for
pelvis scanning than thorax or head scans. This is due to the scanned region being more
central in the voxelised phantom. A head scan occurs at the superior end of the phantom.
So particle scoring at the inferior end of the phantom is significantly less. The effective
dose takes account of dose from organs throughout the body. Using this information it
can be inferred that the uncertainty for pelvis scan effective dose is less than other scan-
ning methods when using MC methods. Although effective dose calculations tend to be
weighted towards the upper half of the body. Simulated pelvis imaging doses are more
accurate for ’whole body organs’ such as skin, muscle, bone, lymph vessels, and marrow.
For the purposes of radiotherapy planning dose is usually given as dose to water. This is
a quantity that can be more easily tied to radiobiological effect. All doses in this study
were given in dose to medium. GATE allows a user to convert dose in medium into dose
to water for conventional dose actors. For seTLE dose scoring such as in the seTLE dose
actor dose to water conversion is not available.
Previous effective dose estimates have been performed using the TrueBeam XI system.93
This study used a physical phantom and performed measurements at one discrete point
within each organ. This estimate is limited in that it does not consider the dose over the
entire organ. Exclusion of the periphery organ dose will lead to considerable uncertainty.
It should be noted that for each scan, out-of-field organ dose have significantly more
noise than in-field organs. This is due to the lower number of photons scored out-of-
field. Despite this the effective dose values from repeat simulations were found to be
reproducible to within .
From observing Figure 4.7 it is clear that the GATE model underestimates the off-axis
ratios with the full bowtie filter in place. The discrepancy between central axis and pe-
ripheral field doses is therefore expected to be overestimated in simulated doses.
MC doses for pelvis, thorax and head scans were converted using calibration factors
97
6 Discussion
determined at nominal exposure values. Due to fluctuations in the tube current the total
mAs delivered during a scan may be reduced by as much as 20 mAs. The sensitivity of the
Monte Carlo conversion factor (equation ??)was tested for a range of delivered exposures
from both the pelvis and head scan protocols. The factor varied by as much as 2.5%. Due
to TLD dose calculations being averaged over repeat measurements the fluctuations. It
is worth noting that the range of variations in exposure had negligible effect on the dose
analysis.
6.2.2 Treatment planning dose summary
A dose-volume histogram (DVH) graphically summarises the the dose distribution within
a volume of interest for plan evaluation. DVHs for organs at risk (OARs) can be used to es-
timate normal tissue complication probability. In this study DVHs for OARs from CBCT
imaging were quantified. This data can be used in addition to DVHs for therapeutic ra-
diation deliveries to more accurately assess clincal endpoints. Doses are presented in dose
to medium due to the inability to simulate dose-to-water when using the seTLE variacne
reduction dose actor. If performed on a more computationally powerful computing cluster
it would be desirable to use conventional dose actors and also enable dose scoring to water.
From observing figures 5.4a, 5.5a, and 5.4c the variation in organ dose from thorax CBCT
can be observed. There is negligible dose sparing of the right lung when the scan centre is
moved from the midlung to the left lung. The only benefit conveyed by shifting isocentre
to the left lung is reducing dose to the spinal cord. As expected the heart dose is greatly
reduced when the isocentre is moved to the right lung.
Obviously DVHs will vary depending on the size of the volume and to what extent the
volume is contoured. The values given in this work are intended to provide estimates for
absorbed dose to different organs due to CBCT imaging. The MC model used here could
also be applied to DVH analysis in actual patient cohorts. The analysis would most likely
be retrospective due to the long computation times from these simulations.
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Head and neck regions contain many critical organs. It has been shown in a study by
Ding et al. that acquiring a 200 degree head scan through the posterior of a patient
will decrease the absorbed dose by the eyes while increasing the spinal cord dose.94 The
maximum dose received by the eyes when treating through the anterior portion of the
face for the Varian OBI (v 1.4) was found to be 0.7 cGy per scan. When performed with
the XI head scan protocol the maximum dose to the left and right eyes was 0.6 cGy.
It is is shown that pelvis CBCT imaging consistently delivers the highest doses to radiosen-
sitive organs. The protocol delivers a higher total exposure than the other protocols and
completes a full rotation around the patient volume. When the prostate is at the isocen-
tre of the scan it is shown in figure 5.5c that the dose received by the OARs in the field
receive a relatively uniform dose across their volumes. The D50% and D10%.
Generally pelvis CBCT are performed on a daily basis for tumour verification. From the
results presented the average doses for the bladder, rectum, and gonads are 19.4 mGy,
17.8 mGy, and 24.6 mGy, respectively. For a conventional prostate treatment, depending
on the risk of the tumour, daily imaging would amount from at least 37 scans to 45 scans.
This would result in a maximum absorbed dose of 0.71 Gy - 0.87 Gy for the bladder, 0.66
Gy - 0.80 Gy to the rectum, and 0.91 Gy - 1.11 Gy for the gonads. For some fractions
multiple CBCTs may be acquired in a single session, further escalating the possible dose.
Obviously DVHs will vary depending on the size of the volume and to what extent the
volume is contoured. The values given in this work are intended to provide estimates for
absorbed dose to different organs due to CBCT imaging. The MC model used here could
also be applied to DVH analysis in actual patient cohorts. The analysis would most likely
be retrospective due to the long computation times from these simulations.
The effect of the treatment planning couch on CBCT dose was examined using the pre-
viously acquired RANDO pelvis simulated dose grid. By monitoring the air-to-entrance
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dose on the posterior and anterior side of teh phantom it was seen that the impact of the
carbon fibre CT couch was negligible.
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There were two objectives in this study: 1) To use the GATE Monte Carlo (MC) toolkit
to construct and validate a Monte Carlo model for CBCT dose calculation and 2) To
perform Monte Carlo dose calculations for site-specific CBCT imaging protocols.
A MC model was constructed of the Varian XI scanner. The x-ray spectra were simulated
for the 100 kVp and 125 kVp beams used for CBCT acquisition. The simulated spectra
were used to parameterise a voxelised source input for the XI beam model. The remaining
components of the beam model were included according to manufacturer documentation.
The results simulated from the GATE model were compared against experimental mea-
surements. PDDs and profiles were compared to assess the dose accuracy of the GATE
model. PDDs matched within 2% while profiles match within 10%. The match for the
head scan protocol seemed to be due to a mismatch between the simulated and experimen-
tal spectra. Therefore, extra validation should be required for verifying energy spectra.
The voxelised source input was unable to model the spatial intensity of photons across
the anode volume or the ’heel effect’.
TLD measurements were performed in the anthropomorphic RANDO phantom to pro-
vide a calibration factor to convert MC dose calculations into absorbed dose. The TLD
dose measurements used in deriving the calibration showed an average difference with
simulated results of 13.7% for pelvis CBCT and 6.4% for head CBCT.
The second part of the study involved calculating population doses within an ICRP phan-
tom. The phantom was imported into the beam model and simulations were performed
using the three XI scan protocols at different isocentres of the phantom. The dose grids
scored over the phantom volume were subsequently analysed for effective dose calculations
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are construction of dose-volume histograms (DVH).
The effective dose given for the head, thorax, and pelvis CBCT imaging was 0.289 mSv ±
0.020 mSv, 1.72 mSv ± 0.07 mSv, and 3.91 mSv ± 0.11 mSv, respectively. Based on organ
and effective dose data it was shown that the absorbed dose was overestimated using the
head CBCT imaging beam model. While thorax and pelvis CBCT imaging showed good
accuracy in calculating in-field organ doses there was less accuracy in determining out of
field organ doses. This was due to the reduction in photon scoring statistics outside of
the field and the discrepancy in the modelling of the heel effect.
DVHs were evaluated for six different sites using the CBCT scan protocols. The D50%
and D10% were calculated for radiosensitive OARs. For pelvis CBCT bladder (D50%=18.7
mGy, D10%=22.4 mGy), rectum (D50%=17.8 mGy, D10%=18.7 mGy) recieved near the
highest organ doses in the volume
There was a significant difference in organ doses during thorax CBCT when the isocenter
was moved between the left lung, mid-lung, and right lung. When moving from midlung
to the right lung the heart dose decreased significantly across the volume. This isocentre
shift also caused a decrease in low dose skin sparring. Shifting between left lung and
mid-lung provided no additional benefit for the heart DVH.
The intention of this component of the study was to provide treatment planning data
for CBCT imaging in common treatment sites. The doses determined were given as the
dose per scan and can be used to estimate the additional dose received by a radiotherapy
patient from imaging
7.1 Recommendations
• Manufacturers should provide published data on x-ray tube spectra for a range of
tube potentials. This would provide a more suitable benchmark for approximating
the spectral distribution from an x-ray tube.
• To address the problems found when modelling the heel effect, it is recommended
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that a phase space be used instead of a voxelised source input. This approach could
be better used to model the spatial intensity of photons across the anode compared
to the voxelised source input.
• To increase the accuracy in simulated results in the anthropomorphic phantom it is
recommended segmentation is used to override the HU values of the water-equivalent
plugs placed in bony anatomy. When surrounded by high Z material HU value of
these plugs will increase. By assigning the correct HU the HU to material conversion
will provide a more accurate dose calculation.
• To improve the tabulated dose statistics given in this study more data needs to be
gathered. By repeating these scans using phantoms of varying size and gender will
enable more accurate reporting for population-based dose statistics.
• As always the limitations of employing a MC model for routine CBCT dose analysis
remain due to the extensive computation time. Even through the use of variance
reduction techniques that greatly improve simulation efficiency, on a standard CPU
simulation times are still extensive. To extend the use of CBCT dose calculations
for patient-specific treatment planning the use of computing clusters and further
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A.1 AAPM TG-61 absorbed dose to water at 2 cm depth
The following worksheets are based on a worksheet given by: The American Association of
Physicists in Medicine (AAPM) Task Group 61 (TG-61). Measurements were performed
on 3 separate occasions against TLD-100s. The beam qualities examined were 100 kV,
7.4 mm Al and 125 kV, 8.0 mm Al. Recombination effects were less than 0.1%. They
were decidely negligible and not considered in the calculation. Polarity correction is not
applicable for the local reference chamber when the calibration polarity is used (-300 V).22
A.1.1 100 kV beam
C.2. TG-61 Worksheet: Calcaulating dose to water at 2 cm depth in water
Name: Luke Gilling Date: 21/02/2018
(1) X-ray unit: Truebeam XI, Tube potential: 100 kV, HVL: 7.4 mm Al, SSD: 100
cm, Field size: 10 x 10 cm2
(2) Ion chamber and electrometer calibration. Date of last calibration: 2018
Ion chamber: IBA FC65-G SN:3681, Calibration factor Nk:=45.02 mGy/nC Elec-
trometer: Fluke Biomedical Advanced Therapy Dosimeter, Model 35040, Calibration
factor Pelec: 1 C/scale unit
(3) Chamber signal: = 1.02 nC
(4) Temperature T = 22.9 ◦C, Pressure P = 100.0 kPa




P [kPa] = 1.02
(5) Total radiation exposure: 1000 mAs
(6) Recombination correction = NA
(7) Polarity correction = NA
(8) Corrected chamber reading M = MrawPelecPTPPionPpol = 1.05 nC
(9) Chamber correction factor (Table VIII, Fig. 4, Table IX):
PQ,chamPsheath = 1.016



















A.1.2 125 kV beam
C.2. TG-61 Worksheet: Calcaulating dose to water at 2 cm depth in water
Name: Luke Gilling Date: 25/02/2018
(1) X-ray unit: Truebeam XI, Tube potential: 125 kV, HVL: 8.0 mm Al, SSD: 100
cm, Field size: 10 x 10 cm2
(2) Ion chamber and electrometer calibration. Date of last calibration: 2018
Ion chamber: IBA FC65-G SN:3681, Calibration factor Nk:=44.95 mGy/nC Elec-
trometer: Fluke Biomedical Advanced Therapy Dosimeter, Model 35040, Calibration
factor Pelec: 1 C/scale unit
(3) Chamber signal: = 1.83 nC
(4) Temperature T = 23.4 ◦C, Pressure P = 100.0 kPa




P [kPa] = 1.03
(5) Total radiation exposure: 1000 mAs
(6) Recombination correction = NA
(7) Polarity correction = NA
(8) Corrected chamber reading M = MrawPelecPTPPionPpol = 1.88 nC
(9) Chamber correction factor (Table VIII, Fig. 4, Table IX):
PQ,chamPsheath = 1.017



















B Uncertainties in experimental measurement
B.1 Relative dosimetry
B.1.1 PDD and profile measurements
Table B.1: The combined uncertainty in relative dosimetry measurements taken using the
CC13 scanning thimble chamber3
Type of quantity or procedure Uncertainty (%)
Repeatability of measurement 1.6
Central axis positioning 0.4
SSD and depth accuracy 0.2
Dose rate variations in x-ray output 2.8
Measurement equipment drift 0.3
Mass attenuation variation with depth 1.0
Combined uncertainty 2.7
Expanded uncertainty (k=2) 5.3
B.2 Absolute dosimetry
B.2.1 AAPM TG-61
Table B.2: The combined uncertainty present when using the AAPM TG-61 reference
dosimetry protocol4
Type of quantity or procedure Uncertainty (%)
Repeatability of measurement 0.2
Nk from standards laboratory 2.1
Chamber correction factor PQ,cham 1.5
Chamber waterproofing sheath correction factor Psheath 0.5
[(µen/ρ)wair]air 1.5
Effect of beam quality difference between calibration
and measurement
3.0
In-water measurement in the user’s beam 2.0
Combined uncertainty 4.7
Expanded uncertainty (k=2) 9.4
C TLD calibration
The calibration work for the TLDs was performed for both 100 kV and 125 kV beams.
TLD-100s were used to conduct the experiment. Sensitivty correction factors were cal-
culated for each energy. The TLDs were then cross-calibrated with dose measured from
an ion chamber using the AAPM TG61 reference protocol. The TLDs were then placed
in the head and pelvis sections of the RANDO phantom from dose measurement. A
summary of the work is seen below
Figure C.1: Sensitivity correction factors
Figure C.2: TLD calibration factors
Figure C.3: Summary of TLD dose measurements performed in the RANDO pelvis phan-
tom
Figure C.4: Summary of TLD dose measurements performed in the RANDO head phan-
tom
D MC dose conversion factors
Figure D.1: 100 kVp, 7.4 mm Al MC calibration factor





# for static acquisitions
#/control/alias TIMESLICE "1 s"
#/control/alias TIMESTART "0.0 s"
#/control/alias TIMESTOP "1 s"
# for full rotation
/control/alias TIMESLICE "0.0372916667 s"
/control/alias TIMESTART "0.0 s"
/control/alias TIMESTOP "13.425 s"
# for 200 deg rotation
#/control/alias TIMESLICE "0.04097985 s"
#/control/alias TIMESTART "0.0 s"






#/control/alias THETA "10. deg"


























































































































































/gate/rot_vol/placement/setRotationAxis 1 0 0
/gate/rot_vol/placement/setRotationAngle 90 deg
/gate/rot_vol/placement/setTranslation 0 0 0 cm
/gate/rot_vol/vis/setColor red
#======================================




#pelvis image measures 241.18x241.18x256 mm
/gate/icrp_phantom/geometry/setImage data/icrp.hdr
#/gate/icrp_phantom/placement/setOrigin -0.1 0 0 mm
/gate/icrp_phantom/geometry/setHUToMaterialFile phantom/icrp_dat2mat.txt









/gate/source/mySource/gps/setSpectrumFile {SOURCE} #125kV.txt or 100kV.txt
/gate/source/mySource/attachTo airSource

































































/gate/btfRotation/placement/setRotationAxis 0 0 1
/gate/btfRotation/placement/setRotationAngle -90 deg



















/gate/w1/placement/setRotationAxis 0 0 1
/gate/w1/placement/setRotationAngle 180 deg










/gate/w2/placement/setRotationAxis 0 0 1
/gate/w2/placement/setRotationAngle 180 deg













/gate/w90/placement/setRotationAxis 0 1 0
/gate/w90/placement/setRotationAngle 180 deg












/gate/phantom/geometry/setXLength 80 cm # make phantom volume extra big to
allow for any translation
/gate/phantom/geometry/setYLength 80 cm
/gate/phantom/geometry/setZLength 80 cm
/gate/phantom/placement/setRotationAxis 1 0 0
/gate/phantom/placement/setRotationAngle 90 deg
/gate/phantom/placement/setTranslation 0 0 0 cm
/gate/phantom/vis/setColor red
#======================================




#pelvis image measures 241.18x241.18x256 mm
/gate/rando/geometry/setImage data/mhd/randopelvis/randoPelvis.mhd
#/gate/rando/placement/setOrigin -0.1 0 0 mm
/gate/rando/geometry/setHUToMaterialFile phantom/rando_dat2mat.txt











/gate/actor/dosegrid/setPosition 0 0 0 cm
/gate/actor/dosegrid/setSize 38.656 38.656 24.2 cm









Figure F.1: Simulated and experimental results for profiles at 1 cm and 5 cm using
the body scan protocol. Not included in the body of the report due to noise in the
experimental data
